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ABSTRACT OF THE DISSERTATION
Nanoparticle Cloaking of Viral Vectors for Enhanced Gene Delivery
by
Ajay Ajit Sapre
Doctor of Philosophy in Bioengineering
University of California, San Diego, 2018
Professor Adam J. Engler, Chair
Professor Sadik C. Esener, Co-Chair
Gene therapy has the potential to treat a wide range of diseases and ailments
from cancer to blindness by altering or overcoming disease at its genetic roots. This
is accomplished by adding or alternating genetic information of diseased tissue or at
a distant site for systemic treatment. Genetically modified viruses are the most effi-
cient tools for delivery of genes, but have significant side effects that have limited the
success of clinical trials. Adenovirus (Ad) is a DNA virus that has been tested in over
xiv
100 clinical trials and is the focus of this dissertation. Innate and adaptive immune
responses, hepatic clearance, and cellular tropism are the primary causes of poor
Ad clinical translation. Cloaking technologies using synthetic or biologic materials
have the potential to overcome these issues. Chapter 2 & 3 describes a method to
address clinical barriers by encapsulating Ad in silica as a nanoparticle formulation.
Silica is biodegradeable, biocompatible, and used in variety of nanoparticle formula-
tions to enhance drug delivery. Silica encapsulated Ad (SiAd) enhances transduction
and expands tropism in vitro. In immune-compromised mice, SiAd enhanced tumor
transduction while reducing liver uptake and in immune-competent mice, SiAd re-
duced both the innate and adaptive immune response against Ad. As a model for
cancer gene therapy, we used Ad expressing TNF-related apoptosis-inducing ligand
(TRAIL) and show inhibited tumor growth with SiAd-TRAIL. In chapter 4, we
explore applying the concepts of the previous chapters to Adeno-associated virus
(AAV), which is another viral vector gaining traction for gene therapy in the clinic
and one that is subject to similar barriers to clinical success as Ad. We explore
exosome membrane cloaking and silica cloaking as methods to enhance AAV trans-
duction in vitro. Overall, this dissertation covers techniques that seek to merge the
efficiency of viral gene expression with the versatility of nanoparticle technology to
address clinical challenges in the field of gene therapy.
xv
Chapter 1
Introduction
1.1 Surpassing Evolution
We now live in an age where evolution is no longer a primary constraint on us
as humans nor on the life we interact with, grow, eat, and use for our musings. We
have gleaned some of the inner workings of biology and discovered tools that allow
us to manipulate genes at will. Genetic aberration is really just genetic diversity in
disguise. The basis for evolutionary success is this genetic diversity, where certain
traits are lost or gained and selected out to pass on to future generations. At present,
we possess the tools to act on these traits in individuals, but the future may hold a
different story when genetic modifications to the human genome pass on from one
generation to the next as permanent, augmented traits. We already do this to other
organisms, whether that is genetically modifying a strain of rice to withstand drought
or the generation of salmon that grow faster than their wild counterparts. It is only
1
a matter of time that we are faced with the reality of genetic engineering in humans.
First, let us focus on the treatment of disease and meaningful patient outcomes.
1.2 Gene therapy
Gene therapy has conceptually been around for over 40 years, but has resulted
in few successful clinical outcomes. In this time the field has tested the boundaries
of clinical trials and the public’s view of scientific research. At its core, gene therapy
seeks to treat diseases derived from aberrant genes: genetic mutations or complete
loss of genetic information. This concept came out of the finding that cells are able to
express foreign DNA and in the late 1960s the discovery that certain viruses are able
to stably integrate their genetic information into cells [1]. Shortly after, the advent
of recombinant DNA, where part of the genomic information of one organism is
expressed in another organism, generally in the form of a plasmid, allowed researchers
to produce any known protein of interest. These findings allowed researchers to
develop viruses which could produce any therapeutic protein. Though a genetic
disease can only be treated if the cause, the deficient protein or mutated sequence
is known. One of the major driving forces that accelerated the gene therapy field,
biotechnology in general, and molecular medicine was the sequencing of the human
genome which essentially opened up the opportunity to act on the 19,000 or so protein
encoding genes in our genome [2]. In the early 1990s the first approved gene therapy
clinical trials went underway and produced underwhelming results [3]. Then the field
2
experienced a major setback with death of 18-year old Jesse Gelsinger in a clinical
trial to treat his partial deficiency of the liver enzyme ornithine transcarbamylase [4].
His death was directly attributed to his severe immune response to the viral vector,
adenovirus, that was used. This event caused the US Food and Drug Administration
(FDA) to create new regulations and review processes for gene therapy trials [5]. It
also left a sour taste in the public’s opinion of gene therapy and the pharmaceutical
industry. Since this incident the field has gone back to understanding viral vector
biology, designing vectors with improved safety, increasing oversight in clinical trials
and developing non-viral vectors.
Gene therapy is an umbrella term that covers many different methods and
technologies. The FDA defines gene therapy as ”the administration of genetic mate-
rial to modify or manipulate the expression of a gene product or to alter the biological
properties of living cells for therapeutic use.” These methods can be broadly catego-
rized as gene replacement, gene addition, altering gene expression, and gene editing
(Figure 1.1)[6]. Gene therapy also includes the field of oncolytic viral therapy where
conditionally replicative viruses are used to kill (lyse,-lytic) cancer cells. Current
legislation only allows gene therapy to be used on somatic cells, where the new or al-
tered genetic material does not pass on to the next generation. This is in contrast to
germ line therapy, where the altered genes do pass on from generation to generation
as permanent changes. Manipulation of cells can occur ex vivo, cells removed from
the source, edited, and re-administered, or in vivo where cells are edited directly in
3
Figure 1.1: (A) Replacement of a mutated protein with a functional one. (B)
Addition of gene to alleviate a deficiency. (C) Altering gene expression though
RNA analogs. (D) Direct gene editing. Reproduced from [6], copyright Discovery
Medicine.
4
an organism. Gene therapy can be further differentiated into methods that use viral
vectors versus ones that use non-viral vectors.
Ideal characteristics of gene therapy vectors include: high gene-transfer effi-
ciency, capacity to carry genes encoding therapeutic proteins, minimal cytotoxicity
or selective cytotoxicity, low immunogenicity, ease of production and scale-up, and
the potential for selective gene delivery.
1.2.1 Viral Vectors
Viruses have been around since the dawn of life, literally. It is surmised
that they may have preceded the emergence of cells [7], [8]. They are everywhere,
affecting every organism on our planet. This long evolutionary history has led to
complex structures, a daunting variety, and mechanisms that are highly efficient.
For the field of gene therapy, this efficiency is the most sought after trait.
Viruses are generally categorized as integrating or non-integrating. Integrat-
ing vectors insert their genetic information into the host genome and result in per-
manent gene expression. Integrating vectors also known as RNA viruses include
retroviruses and lentiviruses [9]. Unfortunately, integrating vectors can randomly
insert and activate proto-oncogenes, known as insertional mutagenesis [10]. However
for permanent gene expression, these are still the vectors of choice. Non-integrating
vectors or DNA viruses such as herpes simplex virus (HSV), vaccinia virus, adeno-
associated virus (AAV) and adenovirus (Ad) are the most commonly tested. Vector
5
choice depends on the application or tissue of interest. Each distinct virus family
and serotype (subtype) has evolved to transduce a particular cell type, known as
tropism. Tropism is mediated by viral coat protein interactions with cell surface
proteins/receptors, which are variably expressed across cell types. Thus if a cell
does not express a particular receptor then that cell cannot be transduced, infected,
by the corresponding virus. Transduction refers to the delivery of foreign genetic
information into a cell using a viral vector.
Chapter 2 & 3 of this dissertation will focus on work using Ad and Chapter 4
will focus on AAV. Both of these vectors are well characterized, relatively easy and
safe to work with in a lab setting.
1.2.2 Adenovirus
Adenovirus (Ad) is arguably the most well characterized and most clinically
tested virus to date. Ad is a large family of viruses which is composed of 51 known
human serotypes that contain linear double stranded DNA at 30-40 kb in length.
These wild type viruses generally cause mild, self-limiting infections of the respira-
tory tract and are common causes of ”colds” [11]. Though each serotype has distinct
tropism, almost all studies and clinical trials use Ad serotype 5 [9], [12], [13]. Ad are
non-enveloped virions with a diameter of 90 nm and a characteristic icosahedral cap-
sid structure (20 triangular faces with 12 vertices) comprised of three main proteins:
hexon, penton and fiber domains [14]. In contrast, enveloped virions are composed
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of a lipid membrane surrounding a protein capsid core. Ad capsid proteins deter-
mine cellular tropsim, specifically the 12 fiber domains that protrude from capsid
core, which bind the coxsackie-adenovirus receptor (CAR) with high affinity. This
triggers subsequent binding of the penton base to αv integrins via a Arg-Gly-Asp
(RGD) motif and leads to clathrin mediated endocytosis (Figure 1.2). Acidification
Figure 1.2: Schematic of Ad transduction. Copyright 2013 Stauss et al. Originally
published in [13] under CC BY 3.0 license.
of the endosome leads to fiber domains separating from the capsid core and disrup-
tion of the endosomal membrane leading to release of the hexon core [14]. Upon
release, the capsid is transported to the nuclear membrane and the viral DNA is
injected into the nucleus. This viral DNA is not integrated into the host genome,
but forms a complex with viral proteins to form an episome. Once viral DNA is
delivered, transcription of the viral genome can occur. Ad genomic transcription can
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be categorized as early and late phases. The early phase consists of transcription of
E1-E4 genes that make the host cellular environment more amenable to viral pro-
duction and replication. This process includes preventing cellular apoptosis (E1b),
inhibiting cellular inflammation (E1a and E1b), and mitigating an immune response
(E2). Once DNA replication is activated, the major late promoter (MLP) is turned
Figure 1.3: Schematic of Ad genome and various modifications for each vector gen-
eration. ITR: inverted terminal repeat, Ψ: packaging signal, MLP: major late pro-
moter, ∆: deletion. Reproduced from with permission from [15], copyright Springer
Nature.
on to allow late stage genes to be transcribed. These genes produce the structural
proteins of the capsid [penton (L2), hexon (L3), and fiber (L5)] and allow for viral
replication. The production of viral progeny leads to cell lysis, the release of ∼10,000
progeny virions per cell, and the spread of viral infection. For gene therapy using
either non-replicative or conditionally replicative Ad (crAd), not all wild-type (WT)
genes are necessary. Deletion of the E1 gene results in a non-replicative virus, one
that cannot produce viral progeny. E3 is also non-essential, thus deletions in both
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E1 and E3 allow for insertion of approximately 8 kb of foreign DNA. This available
cassette is sufficient to produce a variety of proteins. First generation vectors, dele-
tions of E1/E3, have several limitations for use in vivo. Specifically they illicit a
significant immune response and have associated toxicity due to the large backbone
of WT Ad genome. Background levels of E and L genes and the replication of vi-
ral DNA leads to cellular inflammation, specifically cytotoxic T lymphocyte (CTL)
immune response against transduced cells leading to reduced duration of transgene
expression [16]. To overcome some of these problems, a second generation Ad vec-
tor was developed with further deletions in E2 and E4 regions (Figure 1.3). With
these deletions, second generation vectors can accommodate up to 14kb of foreign
DNA, but it was found that these vectors still had associated immunogenicity and
did not significantly prolong transgene expression in vivo [17]. Most recently, a third
generation of Ad vectors was developed. These vectors, known as gutless vectors
or helper-dependent Ads, do not contain any of the Ad viral genome outside of the
inverted terminal repeats (ITRs) and the packaging signal (Ψ) (Figure 1.3). Gutless
vectors can accommodate up to 36 kb of foreign DNA, but require a helper Ad for
propagation [15]. Though these circumvent cellular inflammation, these vectors still
illicit a humoral immune response in vivo. See section ”Barriers to Clinical Success”
for further discussion of immune response to viral vectors.
Ads are used for gene addition, for vaccination and for lytic activity. All
of these methods are dependent on modifications to the Ad genome. Condition-
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ally replicative viruses are designed to replicate in and lyse cells of choice. This is
achieved by using a tissue or tumor specific promoter to limit replication to cells
that are able to activate the promoter, whereas normal or healthy cells are unable
to activate replication (see section ”Cancer Gene Therapy”). Regardless, for both
non-replicative or conditionally replicative Ad, the first barrier to transduction is
cellular tropism as transgene expression or replication can only occur once a virion
has undergone endocytosis and is physically inside a cell.
1.2.3 Adeno-Associated Virus
Adeno-Associated Virus (AAV) was first discovered in the 1960s as a contam-
inant of Ad preparations as small 25 nm particles [18]. Interestingly, these viruses
were found to be non-autonomous. Thus AAV replication can only occur in the pres-
ence of a helper virus such as Ad. To date there have been 12 serotypes identified
and none are associated with a human disease; though, approximately 80% of the
population are positive for anti-AAV antibodies [19]. AAVs are noneveloped, have
an icosahedral structure, and contain linear single stranded DNA at 4.8 kb. The
genome is comprised of two genes, rep and cap. The rep gene encodes proteins nec-
essary replication and the cap gene encodes the three capsid proteins. As with Ad,
the capsid protein variants play a role in AAV tropsim and most studies focus on
AAV2. Table1.1 summarizes the 12 serotypes and associated receptors [18].
The ITR units of the AAV genome contain the elements required for packag-
10
Table 1.1: AAV serotypes and associated recptors. Adapted from [18].
Serotype Receptors
AAV1 23/26 N-linked SA
AAV2 HSPG, FGFR1, HGFR, Integrin V5/51, 37/67 kDa LamR
AAV3 HSPG, 37/67 kDa LamR, HGFR
AAV4 23 O-linked SA
AAV5 23 N-linked SA
AAV6 HSPG, 23/ 26 N-linked SA, EGFR
AAV7 Undetermined
AAV8 37/67 kDa LamR
AAV9 Galactose, 37/67 kDa LamR
AAVrh10 Undetermined
AAV11 Undetermined
AAV12 Undetermined
ing, thus the WT genome can be gutted of all viral coding sequences and the genes of
choice can be inserted between the ITRs [20]. In the absence of a helper virus, AAVs
can induce site-specific integration near AAVS1 on human chromosome 19, though at
low efficiency [21]. If integration does not occur then, the viral DNA is expressed in
an episomal fashion [18]–[20]. Though, through cellular division episomal expression
is diluted over time leaving only expression derived from integration.
Since AAVs are naturally replication deficient and have no known pathogenic-
ity, they are attractive candidates for gene therapy. Most clinical studies focus on
AAV2, due to its broad tropsim, for gene addition. The field is now moving to use
AAVs for clustered regularly interspaced short palindromic repeats (CRISPR)-CAS9
genome editing. As AAVs are small, one drawback is the constrained transgene
size. For example, in the context of CRISPR-CAS9 two AAVs are required (co-
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transduction). In the same vain as with all viruses, cellular tropism and in vivo
immune responses are constraints (see section ”Barriers to Clinical Success).
1.2.4 Non-Viral Vectors
To circumvent some of the hurdles associated with viral tropism and im-
munogenicity, non-viral vectors (NVV) are in development. These vectors can be
composed of a variety of materials from lipids to polymers and aim to deliver DNA
or RNA payloads. Nucleic acids (DNA/RNA) are negatively charged species that
can be complexed or encapsulated in a positively charged carrier i.e. liposomes,
solid lipid nanoparticles, and polyplexes. Though NVV are in theory low cost, easy
to produce at scale, and have low immunogenicity, they are highly inefficient when
compared to viral vectors for transfection [22], [23]. This inefficiency in vivo stems
from numerous barriers: cellular uptake of NVV, endosomal escape, transport to the
nucleus (for DNA), circulation half-life, stability in blood, and cytotoxicity at high
concentrations [22], [23]. Note that a virus’s long evolutionary history have overcome
many of these issues associated with inefficiencies at the cellular level.
1.3 Cancer Gene Therapy
Cancer is a disease that will affect us all, whether friends or family. De-
spite recent advances in the understanding of cancer biology and the development
of new therapeutics, it is still a leading cause of morbidity and the second leading
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cause of death in the United States [24]. It is a complex disease defined by cells
gaining or losing certain characteristics through genetic and epigenetic mutations,
which allow them to proliferate uncontrollably [25]. Traditional means of treatment
include surgery, radiation therapy, and chemotherapy. Both surgery and radiation
therapy can only treat solid tumors that are known and accessible. Chemotherapy
relies on drugs that inhibit cell growth and division (taxanes, anthracyclines, alky-
lating agents), but these agents are indiscriminate and have off-target toxicities. In
the last decade the field has focused on using monoclonal antibodies and immune
checkpoint inhibitors to use a patients immune system to attack their cancer, known
as immunotherapy. Immunotherapy has been very successful in subsets of patients,
but can also have serious side effects [26]. In general the field is moving towards
combination therapy where multiple types of treatments are given to achieve clini-
cal outcomes. Another method that is gaining traction is cancer gene therapy also
known as oncolytic viral therapy is one method to circumvent off-target toxicity
and potentially treat unresectable metastatic disease by using conditionally replica-
tive viruses, which specifically replicate in (kill) cancer cells, but not healthy ones
(Figure 1.4). Not only can oncolytic viruses kill cells, they also can be armed with
immuno-stumiulatory molecules which are produced in conjuction with viral progeny.
Cell lysis also leads to release of cancer antigens that can prime the immune system
to attack the cancer. This finding has lead researchers to explore the use of oncolytic
viruses in combination with immunotherapy.
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Figure 1.4: Schematic of oncolytic viral therapy using conditionally replicative Ad
(crAd).
Conditionally replicative viruses have been tested in the clinic for over 20
years, but have resulted in few clinical outcomes. The first engineered oncolytic
agent to enter clinical trials was a condtionally replicative Ad (crAD), known as
ONYX-015, with a deletion in the E1b region. It was hypothesized that this deletion
rendered the virus replicative in cells deficient in p53, a transcription factor involved
in apoptosis, and is a mutation which occurs in the majority of cancers [12], [27].
Initial studies found this to be true, but clinical trial data and further research
into the mechanism of action found that replication was independent of p53 and
was in fact dependent on the presence of Y-Box Binding Factor 1 (YB-1) [12], [28].
Regardless, ONYX-015 completed phase I and phase II clinical trials in the early
2000s in the US and is an approved therapy in China (known as H101).
Much was learned from these initial trials. The first phase I trial was a
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dose escalation study administered intratumorally (IT) to 22 patients with recurrent
head and neck cancer (HNSCC) [29]. No dose limiting toxicity was found even
at 1011plaque-forming units and the main side effect was flu-like symptoms. As
expected, 21 of the 22 patients had a increase in neutralizing antibodies to Ad and 13
patients already had detectable levels of anti-Ad pre-treatment, but with no observed
treatment response there was no correlation with antibody levels [27], [29]. A phase
II study was subsequently conducted to explore multiple dosing regimens as pre-
clinical animal studies showed improved efficacy with multiple injections. In this
study 40 HNSCC patients were treated either with IT injections for five days or
twice a day for two weeks and found that 14% of patients had an objective response
[27]. Detectable virus in the blood declined after the first cycle, which was attributed
to the striking increase in serum antibody levels. Another trial tested the feasibility
of intravenous (IV) injection and had similar, underwhelming findings. This study
also found an increase in serum aminotransferase levels, an indicator of liver toxicity
[30]. A randomized phase III study was completed in China using an identical virus
(H101) and found a significant benefit, more than doubling the response rate, when
viral therapy was combined with chemotherapy [31]. These studies showed that
Ad administration was well tolerated in patients, that a small set of patients had
responses to ONYX-015, and that combination therapy was a viable option. At the
time of these trials, p53 status was still the basis for understanding the mechanism
of selective replication. Though patients were not compared against or screened for
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p53 status. In addition, tumor CAR expression was unexplored.
Since then, numerous crAds have been designed to address viral tropsim and
selective replication and have entered early phase testing. Some of these iterations
include viruses designed not only with lytic activity, but also the ability to pro-
duce immuno-stimulatory molecules such as granulocytemacrophage colonystimulat-
ing factor (GMCSF) or CD40L [32]–[34]. GMCSF is a cytokine that stimulates
granulocyte and monocyte production leading to antitumor immunity by recruiting
natural killer cells and induction of tumor-specific cytotoxic CD8+ T-cells [33], [35].
Koski et al. also used a chimeric Ad with a Ad serotype-3 fiber domain that binds
to CD46 (not CAR), which may be more broadly expressed on tumors [33]. They
treated 21 patients with Ad3/5-GMCSF and found that 67% had stable disease af-
ter one IT injection. Systemic GMCSF has known toxicity, but systemic GMCSF
was undetectable suggesting GMSCF production was localized to the site of injec-
tion. Again, neutralizing antibodies to Ad increased after treatment. Another group,
Pesonen at al., tested a similar chimeric Ad under a hTERT promoter and expressing
CD40 ligand (Ad5/3-hTERT-CD40L) [34]. Human telomerase (hTERT) is an en-
zyme that essentially allows cells to be become immortalized by preventing telomere
shortening and is a mutation present in over 90% of cancers [36]. Thus an hTERT
promoter restricts Ad replication to cells with this mutation. In addition, the ex-
pression of CD40L augments antitumor immunity. This virus was only tested in nine
patients, but found the virus was tolerated with no significant adverse events. Both
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viral load and serum cytokine levels were found to be low. Overall, these studies
suggest that such modifications to Ad may aid cancer specificity and in inducing the
immune system to aid treatment. Both Koski et al. and Pesonen et al. suggest that
multiple injections are the next step to improving outcomes. Higher viral loads are
required due poor delivery efficiency stemming from tropism, pre-existing antibodies,
viral loss to systemic circulation and liver clearance.
Another virus that has recently attracted much attention is a modified herpes
simplex virus (HSV-1) known as talimogene laherparepvec (T-VEC). HSV is a dou-
ble stranded DNA virus and has much larger genome than Ad at 152kb. The exact
mechanism of action for T-VEC is not completely understood, but it has deletions of
γ−34.5 and ICP6 genes, which remove its neurovirulence and render replication spe-
cific to cells with ribonucleotide reductase expression, respectively [32], [37]. T-VEC
also is armed to produce GM-CSF. A randomized phase III trial was completed where
436 melanoma patients either received multiple IT injections of T-VEC or GMCSF
alone [38]. This trial found that durable response rate (16.3%) and overall response
rate (26.4%) was higher with T-VEC treatment. Adverse events included pain at the
injection site, mild flu-like symptoms and cellulitis. Interestingly, in some patients
treated with T-VEC it was observed that non-injected lesions responded, suggesting
anti-tumor immune response or spread of virions systemically. T-VEC is now the
first FDA approved oncolytic virus for ”local treatment of unresectable cutaneous,
subcutaneous, and nodal lesions in patients with melanoma recurrent after initial
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surgery”. The field is now moving to test this in combination with immunotherapy
and chemotherapy to improve patient outcomes. Though patients are less disposed
to having pre-existing neutralizing antibodies to HSV, they will develop them over
time thus reducing the efficacy of repeat treatments. The approval of T-VEC has
given the field of oncolytic viral therapy and other viral based treatments some hope
though there is still progress to be made.
1.4 Clinical Gene Therapy
In contrast to oncolytic viral therapy (cancer gene therapy), therapeutic gene
therapy seeks to overcome genetic aberrations through gene replacement, gene ad-
dition, gene silencing and gene editing (Figure 1.1). As mentioned previously, viral
vectors are the most efficient tool for all four strategies. In the clinic, these methods
have been tested both as ex vivo manipulation and directly in vivo. This section will
cover some of the most successful clinical attempts to use viral vectors to achieve
these strategies.
Gene replacement is conceptually the simplest form of gene therapy where a
single protein is replaced to achieve therapeutic outcome. This is possible because a
large number of human diseases are defined by a single mutation, monogenic, that
produces a single aberrant protein such as hemophilia. Hemophilia is a monogenic
disease characterized by deficiency in blood coagulation factors, either factor VIII
for hemophilia A or factor IX (FIX) for hemophilia B [39]. It is treatable though
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intravenous (IV) replacement of recombinant FIX or purified plasma throughout the
lifespan of the patient. Thus gene replacement is an attractive method to achieve
long term endogenous production of a single clotting factor. The field has focused
on using AAVs as the vector of choice, either for intramuscular injection (IM) or IV
delivery for transduction of the liver. IM delivery seeks to use skeletal muscle as
endogenous generator of a protein of interest that releases in the circulation and has
a systemic effect. Clinical studies have shown some promise, in one trial bleeding
episodes were reduced up to 90% with the replacement of only 5% of the normal
clotting factor activity [40]. The efficacy of these trials has been hampered by the
finding that AAVs induce a T-cell immune response, which clears transduced cells
and leads to loss of protein expression [39]–[41]. In addition, it was found that
pre-existing antibodies do reduce efficacy of treatment by reducing viral load [39].
The field of gene replacement has also focused on diseases characterized by
enzyme deficiency such as lipoprotein lipase deficiency (LPLD). Patients with this
disease are deficient in an enzyme involved in fat metabolism and are prone to pain
and inflammation of the pancreas. Glybera, the first gene therapy vector approved
in the west, is an non-replicative AAV-1 vector that produces the enzyme lipoprotein
lipase. Clinical trials administered a one time IM dose at multiple injection sites.
Skeletal muscle is easy to transduce and can act as endogenous source of enzyme.
Though Glybera was approved in Europe, its clinical effectiveness is still in question
as the clinical efficacy end point was not durable [42]. This is attributed, again,
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to the immune response and pre-existing antibodies against AAV [42], [43]. Due
to these complications, it is recommended that Glybera be administered along with
immuno-suppressants [43].
Treating inherited blindness, Leber’s congenital amaurosis, is another focus
of the field. This disease is caused by mutations in the RPE65 gene that causes
retinal degeneration from birth [44]. Again, AAV has been the vector of choice.
Clinical trials using subretinal injection found that patients had improved vision
though transient, peaking at 8 months post-injection and then declining [45].
The above examples represent the most successful trials with few ending with
real, substantial patient outcomes. These poor results stem from biological barriers
innate in our physiology.
1.5 Barriers to Clinical Success
Though there are hundreds of clinical trials in progress using viral vectors,
there are still numerous barriers to clinical success and real patient outcomes. These
include native viral tropism, liver sequestration, and induction of innate and adaptive
immunity against viral particles. These factors are not only important for Ad and
AAVs, but apply to all viral vectors. This is especially true for adaptive immunity
i.e. the production of antibodies, which will reduce the efficacy of all vectors over
repeated treatments.
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1.5.1 Tropism
Viral efficacy is essentially a two stage process: the first stage is controlled
by viral entry into a cell and the second stage is controlled by promoter driven DNA
transcription. Independent on how specific this promoter is, if viral entry cannot
occur due to tropism then the virus cannot function. Tropism is defined by the viral
structure, capsid proteins, interaction with cell surface receptors, which is evolution-
arily derived. Cell or tissue expression of such receptors is variable and thus limits
the efficacy of viral vectors in tissues that have low or no receptor expression. For
Ad serotype 5 (Ad-5), tropism is primarily mediated coxsackie-adenovirus receptor
(CAR) expression. It is well documented that cancer cell lines express CAR at vari-
able levels (Figure 1.5) [46], [47]. This is important to note for in vitro studies, but
does not tell the full story for in vivo models or in human physiology. In humans,
CAR is expressed across many tissues, but predominantly in the liver, colon, gall
bladder, esophagus, pancreas, and stomach (Figure 1.6) [48]. These tissues may act
as off-target tissues that can sequester therapeutic Ads from circulation.
In the context of cancers, CAR expression is highly variable across cancers
types, mirroring cell line variability, and across progression of a disease [48]–[51].
In Chinese patients, Ma et al. preformed immunohistochemistry on 251 tissue mi-
croarrays comparing normal tissue to coloretal cancer samples and found decreased
CAR expression in malignant samples [49]. Similarly, in head and neck squamous
cell carcinomas Wunder et al. found the CAR expression correlated with the grade
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Figure 1.5: (A) CAR expression as measured using RT-PCR. (B) CAR expression
as measured by western blotting. Reproduced with permission from [46], copyright
Springer Nature.
of tumor, where well differentiated tumors had higher expression than less differ-
entiated ones [51]. In contrast, Martin et al. found that in breast cancer samples
CAR expression increased with the grade of tumor and if metastasis were present
[50]. Overall, CAR expression is highly variable and cancer type/stage dependent.
The authors from the cited work above all recommended that patients be stratified
according to CAR expression if Ad based therapy were to be used.
For AAVs, tropism is less defined than for Ad-5, where tropism is primarily
defined by cellular glycans. Table1.1 summarizes the 12 serotypes and associated
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Figure 1.6: Percent CAR positive samples from normal tissues determined by
immunohistochemical staining. Reproduced with permission from [48], copyright
Springer Nature.
known receptors [18]. As with CAR, these receptors are variably expressed across
tissues. Most studies have focused on work in vivo in mice models to determine AAV
tropism. Zincarelli et al. examined systemic transduction through tail vein injections
of serotypes 1-9 in mice and found highly variable transduction across tissues and
strong liver transduction for most serotypes [52]. More work needs to be done to
better understand AAV tropism in humans and the impact on clinical outcomes.
1.5.2 Liver Sequestration
As suggested above, the liver is ubiquitous destination of Ad and AAVs that
end up in the circulation. This is mediated by Kupffer cell uptake and by binding
of coagulation factors to the capsid surface resulting in hepatocyte uptake. Liver
sequestration of Ad has been well known since the 1990s and was originally thought
to be primarily due to Kupffer cells in the liver [53]. These cells are specialized
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macrophages that are part of the mononuclear phagocytic system and take part in
many roles, but importantly are capable of clearing particles from the circulation
[54]. Further research found that the primary pathway for liver uptake of Ad was
binding of coagulation factor IX and complement component C4-binding protein to
the capsid structure, which results in robust hepatocyte transduction [55]. This
binding has an affinity that is almost 40-fold stronger than the affinity for CAR [56].
Thus the majority of virions that end up in the ciculation, whether that be from IV
injection or from leakage out of the injection site even when injected IT or IM, are
cleared by the liver and result in liver transduction [57]. This transduction results
in hepatotoxicity and inflammation [55], [58].
AAV is plagued by the same mechanism. In a clinical trial to treat spinal
muscular atrophy with a single high dose of AAV-9 delivered IV, patients had elevated
transaminase levels (a measure of liver toxicity) [59]. This was recently supported by
a study in non-human primates (NHP) and piglets, where animals were IV injected
a high dose of AAV-9 [60]. Again, animals had elevated transaminase levels and one
NHP had to be euthanized four days post-injection due to acute liver failure.
1.5.3 Innate and Adaptive Immune Response
The biggest downside to the use of viral vectors for in vivo gene therapy
is the innate and adaptive (humoral) immune response. Our bodies have evolved
to fight and adapt to invading pathogens whether that is novel virus serotypes or
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ones that our immune system has seen previously. This was clearly demonstrated
as the main factor for Jesse Gelsinger’s death the OTC clinical trial where a high
dose of Ad was directly injected into his hepatic artery. Within days his severe
immune reaction induced a coma and eventual death. This result was from both
innate and adaptive immune components. Innate responses are non-specific and
act on all foreign objects. It is comprised of anatomical barriers (i.e. mucus), the
complement cascade, and variety of leukocytes: natural killer (NK) cells, mast cells,
eosinophils, basophils, macrophages, neutrophils, and dendritic cells. Whereas the
adaptive immune system is specific and long-lasting with memory. It is comprised of
lymphocytes (a variety of T cells and B cells) and antibody production/recognition.
Both these systems compliment each other though a complex web of interactions.
This section will review the relevant components related to Ad and AAV induced
response.
Table 1.2: Innate Immune Cytokines. Adapted from [61].
Cytokine Function/Pathway
IL-1 Proinflammatory, endogenous pyrogen
TNF-α Induces apoptosis
IL-6 Secreted by macrophages, induces fever
IFN-γ Activates macrophages, induces MHC expression
IL-12 Stimulates T cells and NK cells
IP-10 Chemoattractant for neutrophils
RANTES Chemoattractant, recruits leukocytes
MIP-1 Chemoattractant for NK cells
MCP-1 Chemoattractant for monocytes
The method of injection does influence the overall immune response as the
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viral load in the blood correlates to the amount of virus that can be initially acted on.
Even with direct tumoral injections viruses are released to the circulation though at
a lower load. Thus, the innate immune reaction is considered dose dependent and is
triggered upon cellular transduction at the site of interest or in the liver. The primary
cytokines and chemokines involved include: tumor necrosis factor α (TNF-α), IL-6,
IL-1, interferon γ (IFN-γ), IL-12, macrophage inflammatory protein (MIP)-2, IFN-
γ-inducible protein 10 (IP-10), RANTES (regulated on activation, normal T cell
expressed and secreted), MIP-1α, MIP-1β, and monocyte chemo-attractant protein
1 (MCP-1) [61]. See Table1.2 for overview. At a cellular level, a cell initiates the
innate immune response upon viral binding and endocytosis of a virion. Recognition
of foreign DNA by toll-like receptors induces interferon pathways and IL-1 production
[62]. It was found that the capsid proteins alone, without viral replication or viral
gene expression, can induce a similar innate response suggesting that capsid proteins
themselves play an important role [61]. This complex milieu of molecules can be
measured within hours of Ad transduction.
Once the innate cascade is triggered, activation of CD4+ and CD8+ T cells,
and B cells (of the adaptive immune system) can occur. This takes places through
a helper T cell I (Th-1) response that is proinflammatory and occurs in response to
most pathogens. CD8+ cytotoxic T lymphocytes (CTL) play a role in clearing trans-
duced cells which limits transgene expression [64]. Dendritic cells (DCs) are critical
to the adaptive response and act as a antigen presenting cell (APC) through MHC
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Figure 1.7: Overview of immune response to viruses. Reproduced with permission
from [63], copyright 2014 McGraw-Hill Education.
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class II upregulation [65]. APCs digest pathogens and present fragments as antigens
on their surface to interact with helper T cells. These cells release interleukins that
activate B cells. Once B cells are activated they can proliferate and mature into
plasma cells, which secrete antibodies against the antigen. See Figure 1.7 for review.
Neutralizing antibodies play an important role in clearing viral particles against
a second and subsequent infections. For Ad, antibodies are generated against the
fiber and hexon proteins. It is believed that fiber antibodies cause viral aggregation
and block CAR receptor binding. Ad infections are believed to be quite common
and is reflected by the presence of neutralizing antibodies in the majority of patients.
Bauer et al. found that 98.8% of the 667 human patient samples tested, not selected
for viral infection, had antibodies to Ad-5 hexon proteins [66]. They also found that
these samples had varying degrees of antibodies to other Ad serotypes. Similarly, Yu
et al. found that 90% of samples tested positive for anti-fiber antibodies [67]. The
prevalence of antibodies is an important consideration especially for IV injections,
but also for IT and IM injections. Multiple injections are now the standard procedure
tested in clinical trials, which only augments antibody production and the potential
for inflammation.
Immune responses to AAV follow a similar fashion. AAV2 antibodies are
prevalent in humans and AAVs have a high degree of conservation between serotypes
leading to cross reactivity of antibodies [68]. Studies have found that in both humans
and animal models that low levels of antibodies are able to neutralize large doses or,
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in clinical trials, prevent transgene expression [69], [70]. Thus for all vectors, patients
with pre-existing antibodies are less likely to have successful outcomes.
1.6 Overcoming Clinical Barriers
1.6.1 Capsid Modification
Natural viral vectors all have evolutionary constrained tropism and can initi-
ate an immune response. To overcome some of the issues related to tropism, chimeric
viral capsids or directed viral evolution have been tested. Chimeric capsids are com-
posed of multiple serotype components, in general, the field has focused on fiber
domain replacement or modification. For example, in a clinical trial (mentioned
above) researchers used a chimeric Ad with an Ad-5 backbone and a Ad-3 fiber do-
main to transduce cells through the CD46 receptor [33]. Others have modified the
fiber domain with lysine motifs, RGD peptides, or with a Sigma knob [71]. Mod-
ification of the fiber can in theory allow a variety of receptors to be targeted, but
is balanced against downstream structure-function relationships between capsid pro-
teins. To take chimeric capsids one step further, Grimm et al. used DNA family
shuﬄing technology to create a library of AAV capsids derived from five different
serotypes [72]. Selection against human hepatocytes revealed a type 2/type 8/type
9 chimera called AAV-DJ, which enhanced transduction across cell lines. Directed
evolution has also been tested to create new Ads. This approach uses selective pres-
sure to generate mutations in Ads that enhance transduction, lytic activity, or even
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ones resistant to antibody neutralization [73]–[75]. These approaches may expand
viral tropism, but they do not overcome liver clearance and activation of an immune
response.
A common technique to increase the circulation half-life of proteins, enzymes,
and nanoparticles is to covalently modify the surface of such with poly(ethylene gly-
col) (PEG). PEG is a hydrophilic polymer that creates a hydration layer on the
surface of particles and inhibits adsorption of proteins. This polymer can be congu-
jated to surface amine groups through N-hydroxysuccinimide chemistry. For Ad,
surface amines occur in both the hexon and fiber domains. Though chemical conju-
gation to capsid proteins disrupts efficient binding to CAR and reduces tansduction
efficiency, in some cases completely ablating it [76]. Studies have shown that PEGy-
lated Ad also has reduced liver uptake, due to both reduced overall tansduction and
from the PEG hydration layer [77].
1.6.2 Nanoparticle Formulations
Methods to overcome an immune response, outside of using purely non-viral
vectors, include shielding or encapsulation of virions in nanoparticles. Nanoparti-
cles can be composed of a variety of organic and inorganic materials such as lipids
(liposomes), metals, polymers, and silica. Most studies have focused on the use of
polymers to shield Ad. This shielding is accomplished through the use of electro-
static interactions where positively charged polymers are complexed with negatively
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charged Ad [78], [79]. Poly(ethylenimine) (PEI) and poly(l-lysine) (PLL) are pos-
itively charged polymers that have been tested in this context. Molecular weight
and degree of branching are important parameters to consider as both influence the
degree of toxicity [80]. These polymer complexes work well in vitro to enhance trans-
duction, but are quickly cleared in vivo from adsorption of plasma proteins to the
positively charged surface. Enhanced transduction is believed to be caused by the
cationic polymer interacting with the anionic cell membrane inducing non-specific
uptake [81]. PEGylation of the polymer surface can increase circulation half-life, but
again hampers transduction. Using electrostatic interactions to ”coat” Ad is a sim-
ple approach, but produces particles with surfaces that are brush-like and capable
of adsorbing unwanted proteins.
1.6.3 Silica Nanoparticles
Silica is another material that has been explored for numerous nanoparticle
formulations for drug delivery and imaging, but not for encapsulation of Ad [82]. In
this context, specifically for drug delivery, mesoporous silica nanoparticles (MSNs)
have many advantages such as large surface area, adjustable pore size and volume,
easy modification of surface properties through silanol chemistry, and acceptable in
vivo biocompatibility and biodegredation [82], [83]. Traditional synthesis methods of
MSNs use a template driven approach where templates consist of cationic surfactants
or of solid cationic polymeric nanoparticles. Silicate precursors, commonly tetraethyl
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orthosilicate (TEOS) or tetramethyl orthosilicate (TMOS), are hydrolyzed in solution
and produce anionic species or silanol groups (Si-OH). Silanol groups react with each
other known (Si-OH + OH-Si) as water condensation or react with methoxy groups
(Si-OH + Si-OCH3) known as alcohol condensation. Reaction using TMOS shown
below.
Si(OCH3)4 + H2O
hydrolysis−−−−−→ Si(OCH3)3OH + CH3OH
Si–O–H + H–O–Si
water condensation−−−−−−−−−−→ Si–O–Si + H2O
Si–O–H + H3C–O–Si
alcohol condensation−−−−−−−−−−−→ Si–O–Si + CH3OH
Both TEOS and TMOS are tetra-valent, with four reactive groups where initial
condensation reactions produce nucleation sites which then enter a growth phase. At
a pH above the isoelectric point (pH = 2) of silanol groups, these silicate precursors
are negatively charged [84]. If a cationic substrate is present then these precursors
will condense via electrostatic interactions. Cationic surfactants can form a variety of
structures in solution, as emulsions, from micelles to rods and act as a soft template
whereas cationic polymeric nanoparticles act as a hard template. Once condensation
of silica has completed the templates may be removed using an etching process with
the use of solvents or high temperatures to produce hollow porous nanoparticles [85].
These hollow porous particles can act as drug delivery vehicles or successfully shield
enzymes from immune recognition [86].
The use of viruses, specifically the plant viruses: tobacco mosaic virus (TMV)
and cowpea mosaic virus (CPMV), have been used as silica nanoparticle templates,
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but for applications outside of medicine [87], [88]. To template silica onto the surface
of TMV, pH has been used as driving force [88]. In the case of CPMV, surface
modification directly to the capsid proteins has been used to create a charge difference
[87]. In both cases the capsid surface acts as template for silica deposition. The use
of other viruses has not been reported.
In the context of Ad, only large silica sol-gel implants have been tested as
viral depots [89]. These implants were reported to be very large (7 - 11mm) and
required surgical implantation. These implants were formed by pre-making a silica
gel and then mixing in viral stock solutions. This mixture was then put into a mold
and cooled to form a gel made of 90% water. This delivery system did improve
viral kinetics by extending the duration of virus present at the surgical location, but
this system does not address the issue of Ad viral tropism and it was found that
significant liver transduction still occurred.
1.7 Scope of Dissertation
The work presented in this dissertation covers methods which seek to over-
come some of the clinical barriers associated with viral vector gene therapy. Chapter
2 and Chapter 3 of this dissertation will cover a technique to encapsulate Ad in silica
as a nanoparticle formulation. Chapter 2 focuses on optimization of silica coated Ad
(SiAd), characterization using techniques designed for nanoparticles and viruses, and
covers experiments performed in vitro to elucidate SiAd’s characteristics. Chapter
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3 covers experiments performed in vivo in both immune compromised and immune
competent mouse models to evaluate the bio-distribution of and the immune response
to SiAd. Chapter 4 focuses translating the knowledge gained from Chapter 2 to de-
velop methods to encapsulate AAVs in silica or in exosomal derived membranes as
way to enhance transduction in vitro.
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Chapter 2
Synthesis, Characterization, and In Vitro
Study of Silica Cloaked Adenovirus
2.1 Synthesis of SiAd Nanoparticles
The first experiments performed on synthesizing silica coated Adenovirus
(SiAd) were done by Gen Yong, PhD. His thesis (Nanoparticle Formulations for
Cancer Therapy, UCSD, 12-Dec-2013) outlined a basic method of synthesis which
was expanded upon and explored more here [1]. The core concept behind SiAd
formulation is to control silica deposition using surface charge in a template driven
manner. This idea was explored in depth by Inanc Ortac, PhD and Ya-San Yeh,
PhD for sealing of hollow mesoporous silica nanoparticles [2], [3]. As traditional
methods of silica nanoparticle (Sto¨ber method) involve solvents and are incompati-
ble with biological entities, we employed a method that is completely aqueous based
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and compatible with enzymes and viruses.
Figure 2.1: Using the native negative charge of Ad, we first complex it with the
positively charged polymer, poly-L-lysine (PLL). Next, we add silicic acid (activated
TMOS) to induce silica deposition onto the Ad/PLL surface.
The silica reaction we employed is a bulk solution reaction where hydrolyzed
tetramethyl orthosilicate (TMOS) condenses in solution. In general, TMOS is acid
hydrolyzed in 1 mM hydrochloric acid (HCl) to form highly reactive silicic acid.
Nucleation and condensation of silicic acid form precursors to pure silica particles
which are negatively charged. If cationic species are present then these precursor
particles will condense near such species via electrostatic attraction. If no cationic
species are present then these precursor particles will continue to grow and form free
silica nanoparticles. Thus there is a competition between directing silica deposition
on a desired surface and free silica condensation. Minimizing free silica formation is
an important parameter, but not at the expense of incomplete silica deposition or
sealing. Thus the surface charge or zeta potential of the template is a defining design
parameter.
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In the case of Ad, the viral capsid can only act as a template for silica once
the surface has been converted to cationic (Figure 2.1). Technically any positively
charged polymer such as poly(L-lysine) (PLL), poly(ethylenimine) (PEI), or chitosan
can be used in this context. Here we used PLL to mask the negatively charged Ad
surface. PLL is a polymer of repeating lysine residues that can be purchased at
various molecular weights (MW) or chain lengths. Traditionally PLL (300,000+
MW) was purchased from Sigma-Aldrich Co. LLC. (St. Louis, MO) as a lyophilized
powder that was reconstituted in sterile water to make a 1% w/v solution. This
solution was further diluted to make a 0.1% w/v solution in sterile filtered water.
Ad expressing green fluorescent protein under a CMV promoter (Ad-GFP)
was purchased from Vector Biolabs (Malvern, PA). This stock was supplied at 1x1010
PFU/ml and upon arrival dispensed in 10µl aliquots and stored at -80C. Unless noted,
for each experiment 10µl was split equally where 5µL was used to make SiAd and the
other 5µl used as Ad control. For all tansduction experiments, cells were plated the
previous day and subsequently transduced for 48 hours. In general, cells were plated
at 90% confluence in 12 well plates. At the time of Ad or SiAd addition the media
was replaced. The multiplicity of infection (MOI), the number of viral particles per
cell, was based off the number of cells plated, e.g., to achieve a MOI of 1 for 100,000
cells then 1µl of Ad/SiAd (5µl stock diluted to 50µl gave 1x106 PFU/µl) was used.
Cells were then visualized using confocal microscopy (Nikon A1R Confocal STORM)
and measured using flow cytometry (BD FACSCalibur) for fluorescence. For each
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parameter a minimum of 75,000 cells were analyzed in duplicate. Geometric mean
fluorescence of all the cells measured is reported due to the finding that some cells
transduced with SiAd had fluorescence values greater than 104. Unless stated, A549
(lung adenocarcinoma) cell was used as this cell line is easily transduced by Ad. Both
neat Ad and cells treated with PBS alone serve as controls for all FACS experiments.
Downstream FACS analysis was performed using FlowJo software (Ashland, OR).
Gen Yong, PhD outlined a procedure in ”Nanoparticle Formulations for Can-
cer Therapy” to encapsulate Ad in silica where 10 µl or 1x108 PFU Ad stock was
incubated with 1.5 uL of 0.1% PLL for five minutes and then a solution of silicic
acid was added, 13% v/v TMOS hydrolyzed in HCl. This mixture was diluted to
a total of 60 µl and vortexed at room temperature for one hour. Then the solution
was spin purified at 14,000 rpm, 4◦C for 5 minutes and resuspended to 50 µl in PBS.
Attempts to produce SiAd, using the outlined method, with enhanced transduc-
tion were unsuccessful. As expanded tropism and enhanced transduction were some
of the primary findings from preliminary testing of SiAd, optimization of reaction
conditions was explored.
2.2 Optimization of SiAd Reaction Conditions
First, the individual chemical constitutes were tested on Ad to see how each
affect transduction. As expected, Ad easily transduces A549 cells (Figure 2.2A blue
line). Ad treated with 1 mM HCl or vortexed at room temperature (RT) for two
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Figure 2.2: (A) FACS histogram, GFP fluorescence, of various conditions. (B)
FACS scatter plot of Ad control and Ad treated with TMOS.
hours had no effect on overall transduction (Figure 2.2A, black line and orange line,
respectively). When neat TMOS (not prehydrolyzed in HCl) was added to Ad at the
same concentration used for SiAd, transduction was essentially ablated suggesting
that PLL is necessary and provides a protective layer to the viral capsid (Figure
2.2B). It is possible that TMOS methoxy groups, once hydrolyzed in water, can
react with any free hydroxl groups present on the capsid surface such as serine or
threonine, which subsequently disrupt viral function. Some groups have shown the
PEI complexed with Ad via electrostatic interaction enhances transduction [4]. As
a proxy, concentrations of PLL were mixed with stock Ad for 15 minutes and trans-
duction was tested on A549 (Figure 2.3). Surprisingly, no amount of PLL enhanced
transduction. Just as PEI is toxic at some level, likely the higher PLL concentrations
tested were also toxic. The samples with the lowest PLL concentrations performed
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Figure 2.3: Transduction of Ad complexed with various concentrations of PLL.
None of which enhanced transduction.
the best, 2 µl and 4 µl of 0.1% PLL. Suggesting that high PLL concentrations were
not suitable for silica coating if toxicity was induced. PLL alone as a coating was
not explored further.
2.2.1 Trypsin Treatment Test
To develop an easy and quick method of testing silica encapsulation and sil-
ica’s protective qualities, we employed the use of trypsin as suggested by Yu-Tsueng
Liu, PhD. Trypsin is an ubiquitous enzyme used in standard cell culture procedures
to detach cells and is easily inactivated by the addition of cell culture media. This
proteolytic enzyme is a serine protease that cleaves peptides after arginine and lysine
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residues. [5]. We hypothesized that if silica does deposit on the capsid surface then
Figure 2.4: Transduction measured before and after 0.25% trypsin treatment for 1
hour (A) Ad (B) SiAd vortexed for 90 minutes (C) SiAd vortexed for 140 minutes.
the capsid proteins would be protected from proteolysis by trypsin. When Ad was
incubated with 0.25% trypsin for one hour at 37◦C there was a 5.55 fold change in
transduction as measured by the difference in geometric mean fluorescence without
and with treatment on A549 cells at a MOI of 50 (Figure 2.4A). All geometric mean
fluorescence measurements were measured using FlowJo software. The influence of
the silica reaction time was tested to see if longer reaction times deposited more
silica. Standard SiAd was made for 90 minutes and for 140 minutes. Transduction
was compared with and without trypsin treatment (Figure 2.4B & C). Though there
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was less overall transduction as compared to Ad, there was a decrease in the loss of
transduction post trypsin treatment. This was further enhanced with a longer reac-
tion time where the fold change for standard SiAd (90min) versus SiAd220 (140min)
was 3.77 and 1.64, respectively. This suggested that silica does provide a protective
mechanism against trypsin treatment. This was further explored as tool for testing
encapsulation.
2.2.2 Reduction of Silicic Acid
It was hypothesized that the original formulation tested by Gen Yong had ex-
cess silica leading to large particles and free silica formation. Traditionally nanopar-
ticle size is quickly and easily measured using dynamic light scattering (DLS). This
measurement uses a cuvette where the smallest cuvette takes a minimum of 70 µl.
To achieve sufficient signal and correlation, a full 5 µL of Ad stock must be used or
the full sample of one SiAd condition. To save viral stocks, polystyrene beads were
tested to determine if the reagents, TMOS and PLL, were in good condition and the
amount of free silica formation. Ya-san Yeh, PhD provided hollow mesoporous silica
particles (HMSP) to test sealing conditions on. HMSPs were diluted to a similar
concentration as Ad viral stock and resuspended in DMEM containing 2 % BSA,
2.5% glycerol in order to mimic Ad conditions. SEM revealed a film coating HMSPs
from just the media alone (Figure 2.5A). Using Malvern Zetasizer, the size was 400
nm and the zeta potential was -9.8 mV. Two reactions conditions were tested for
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Figure 2.5: (A) SEM of HMSP diluted in DMEM with 2 % BSA, 2.5% glycerol. (B)
SEM of HMSPs sealed with less silicic acid, 7.4% v/v. (C) SEM of HMSPs sealed
with Yong’s formulation, 13% v/v.
sealing with silicic acid. Gen Yong’s SiAd formulation used 1.5 µl of 13 % v/v silicic
acid (14.8 µl TMOS in 100 µl 1mM HCl or 3.7 µl TMOS in 25 µl 1mM HCl) for 10
µl Ad stock (108 PFU). When tested on HMSPs this concentration of silica did seal
the HMSPs, but produced excess free silica formation as seen in Figure 2.5C as the
”popcorn” like background. A lower concentration of TMOS was tested at 7.4% v/v
(2 µl TMOS in 25 µl 1mM HCl). This also sealed HMSPs, but with less excess silica
and with a zeta potential of -7.5 mV (Figure 2.5B). Sealing of HMSPs serves as a
proxy for coating of virions.
This finding was then translated to coating of Ad. The silica reaction proce-
dure was carried out keeping all parameters constant except for the concentration of
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silica used. The particles were test on A549 cells at a MOI of 50 and transduction
measured at 48 hours using FACS. When 7.4% v/v silicic acid was used transduc-
tion was significantly enhanced as compared to SiAd made with 13% silicic acid
(Figure 2.6). Though overall transduction was not enhanced over Ad. Interestingly,
there appears to be a population of cells that are super transduced with SiAd, these
cells appear with fluorescence greater than 104. These cells are likely transduced by
particles that contain more than single virions. In addition to reducing the silicic
Figure 2.6: Comparing transduction of Ad, SiAd original formulation and SiAd
made with less silica.
acid concentration, the length of PLL incubation was increased from 5 minutes to
15 minutes to insure sufficient interaction between negatively charged Ad and pos-
itively charged PLL. This new formulation with reduced silica (SiAdv2) was tested
against trypsin to determine silica encapsulation. Surprisingly with trypsin treat-
ment on SiAd formulations with longer PLL incubation time resulted in an increase
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Figure 2.7: Transduction measured before and after 0.25% trypsin treatment for 1
hour (A) Ad (B) SiAd220 (13% silicic acid) (C) SiAd74 (7.4% silicic acid).
in transduction. The fold change in transduction, without treatment/treatment, for
SiAd220 and SiAd74 was 0.4 and 0.7, respectively (Figure 2.7A, 2.7B). Considering
trypsin can cleave PLL, this suggests that trypsin may actually be breaking up ag-
gregates of SiAd particles that are joined by PLL strands. This is also supported by
the reduction in super bright cells, fluorescence greater than 104, after trypsin treat-
ment. Again, this population of cells are ones likely transduced by multiple virions,
which are likely aggregates of SiAd particles. Less silica and longer PLL incubation
improved SiAd transduction with overall transduction efficiency approaching that of
Ad (5.5±1.3 vs. 8.7±1.2 geometric mean fluorescence of total cell population).
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Dynamic light scattering (DLS) was used to test the effect of the amount of
silicic acid (SA) at this reduced concentration, 7.4%, had on particle size. At the
amounts tested, particle size was comparable (Figure 2.8).
Figure 2.8: Particle size is independent of silicic acid amount. Measured by DLS.
2.2.3 PLL Chain Length
We hypothesized that the PLL chain length could have an effect on the coating
process. PLL was purchased at three different chain lengths: 30-70k MW, 70-150k
MW and 300k+ MW. Each was reconstituted in sterile water at 1% w/v. Tradi-
tionally 300k+ PLL was used for synthesis of hollow mesoporous silica nanoparticles.
PLL is known to form nanoparticles in solution. Hydrodynamic radius, measured
with DLS, revealed that both 30-70k PLL and 70-150k had aggregates of PLL and
large distribution of particles (Figure 2.9 and 2.10). Interestingly, DLS of 300k+ PLL
revealed a population of particles that was around 1nm and a small population of
aggregates (Figure 2.11). To minimize the downstream particle distribution, 300k+
PLL was used for all experiments.
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Figure 2.9: Hydrodynamic radius of 30-70k PLL in water.
Figure 2.10: Hydrodynamic radius of 70-150k PLL in water.
We tested both the 30-70k and 70-150k PLL to see the effect of PLL chain
length on SiAd transduction. Stock solutions were made at 1mg/ml in sterile water.
Assuming 300k+ PLL had a molecular weight of 300,000 g/mol, that 70-150k PLL
had a molecular weight of 110,000 g/mol, and that 30-70k had a molecular weight
of 50,000 g/mol, we normalized all PLL concentrations to the standard formulation
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Figure 2.11: Hydrodynamic radius of 300k+ PLL in water.
using 5x10−12 mol of each. We tested transduction on A549 cells as a measure of
efficiency and found only particles made with 300k+ improved transduction over
neat Ad (Figure 2.12).
2.2.4 PBS Concentration and Optimized SiAd
Improved transduction with less silicic acid suggested that free silica formation
and/or a thick layer of silica is inhibitory to Ad transduction. Yasan Yeh, PhD found
that reducing the ionic strength of the solution during the sealing process produced
less free silica in solution [3]. Though, performing the reaction in pure water did not
seal HMSPs suggesting that dissolved salts act as silica precursor nucleation sites.
Thus, SiAd made in 0.05x PBS (5% PBS in sterile water) was tested. To maximize
the number of experiments derived from Ad stock, all future experiments used 5 µl
Ad stock or 5x107 PFU. Subsequently, TMOS was hydrolyzed at 3.6% v/v (1.8 µl
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Figure 2.12: SiAd was made with three different PLL chain lengths: 300k+ PLL
(300k), 70-150k PLL (150k) and 30-70k PLL (70k). Lysine amount was normalized
to the concentration used for 300k formulation. Transduction was tested on A549.
in 48.2 µl 1mM HCl for 1 minute) and the total reaction volume was reduced to
30 µl. First, Ad was incubated with 1.5 µl of 0.1% PLL for 15 minutes and bath
sonicated (QSonica, Newton, CT) on low power for 3 minutes. Then 1.5 µl of 3.6%
v/v silicic acid was added. This mixture was then diluted to 30 µl in total in 0.05x
PBS and vortexed for 140 minutes. Post-vortexing the solution was centrifuged
Figure 2.13: Supernatant was collected after centrifuging SiAd and tested on A549
cells.
at 14,000 rpm for 30 minutes at 4◦C. Post-centrifugation, 27 µl of supernatant was
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Figure 2.14: Optimized synthesis of SiAd produced particles that enhanced trans-
duction on A549 cells. Histograms of GFP positive cell population at various MOIs
(A) Ad and (B) SiAd. (C) Geometric mean fluorescence of total cell population at
same MOIs for Ad, grey bars, and SiAd, black bars. (D) Confocal images of Ad and
SiAd at MOI 50.
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removed and replaced with 47 µl of PBS. To ensure maximum collection of SiAd
particles during spin purification the spin time was increased from 5 to 30 minutes.
It was suggested that SiAd would not ”pellet” at 14,000 rpm, but the supernatant
was collected from SiAd and tested for transduction. No significant transduction
was found (Figure 2.13). Changing the reaction media to 0.05x PBS significantly
improved the transduction of SiAd (Figure 2.14B). This optimized formulation also
had enhanced transduction vs. Ad for all MOIs on A549 cells and confirmed with
confocal microscopy (Figure 2.14C & D).
2.3 Characterization of SiAd
2.3.1 Transmission Electron Microscopy
Transmission electron microscopy (TEM) is a standard method for visualiza-
tion of viruses and nanoparticles that cannot be resolved using light. Image contrast
is dependent on electron density of the sample. Biological entities i.e. proteins,
provide poor contrast and the use of a negative stain such as uranyl acetate is the
standard method to stain proteins. Images were taken on a FEI Sphera (UCSD)
operating at 200 kV or FEI Technai (OHSU) operating at 120 kV. Copper grids
(formvar/carbon-coated, 400 mesh copper, Ted Pella) were prepared by glow dis-
charging the surface at 20 mA for 1.5 minutes. Then 3.5 µl of sample was placed
on the grid and allowed to sit for 30 seconds. The solutions were wicked away and
washed with water. For imaging of naked Ad, grids were treated with three drops of
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1% w/w uranyl acetate to provide negative staining. Ad has a distinct icosahedral
Figure 2.15: (A) Crystal structure of Ad. TEM of Ad stained with uranyl acetate
(B) and of SiAd unstained (C, D, E, F). Representative images of particles likely
containing a single virion (C, D, E) and a representative image of a SiAd particle
likely containing multiple virions (F). All scale bars represent 100 nm.
shape consisting of hexon proteins with fibers at each vertex. The crystal struc-
ture of Ad (10.2210/rcsb pdb/mom 2010 12) is known (Figure 2.15A). TEM of Ad
stained with uranyl acetate revealed the classic icosahedral shape though without
the resolution of the fiber domains (Figure 2.15B). As silica is electron dense enough
to provide contrast in the context of silica nanoparticles, SiAd particles were imaged
neat without the use of negative stain. TEM revealed particles that retain similar
shape and size as Ad. In Figure 2.14C and Figure 2.15D, spikes protruding from
particles appear to be fiber domains coated in silica. The preservation of capsid
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proteins is important to retain further downstream function of Ad. In both Figure
2.15D and 2.15F, small 10 nm sized particles are seen littering the background.
These small particles are free silica. In Figure 2.15F a particle which likely contains
multiple virions can been seen. It is expected to have a distribution of particle sizes
considering the silica reaction is a stochastic process which is directed by electrostatic
interactions and the because reaction is performed in bulk.
2.3.2 Particle Size and Charge
TEM is an effective technique for qualitatively evaluating particle morphol-
ogy, but a large number of images need to be taken in order to calculate average
particle size. One standard technique to measure particle size is dynamic light scat-
tering (DLS) which measures hyrodynamic radius of particles in solution based on
Brownian motion. For DLS measurements on a Malvern Zetasizer ZSP instrument
a sufficient concentration of particles is required to get a viable correlation function.
Unfortunately the total SiAd sample was required (5 µl of Ad stock) to achieve suf-
ficient concentration even when using a small volume cuvette (70 µl). A significant
limitation of DLS is that resolution is limited to particles that are more than three
times larger than other particles in solution. Thus, polydisperse samples that contain
particles in a range less than a factor of three are not represented properly in DLS
measurement.
To get a better representation of the particle size distribution of SiAd, the use
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of nanoparticle tracking analysis (NTA) was explored. NTA uses a laser to illuminate
the sample, a microscope to visualize particles in solution and a camera to record
videos of the particle’s Brownian motion. Knowing the temperature and viscosity
of the solution allows NTA to calculate particle diameter using the StokesEinstein
equation and is not limited to monodisperse samples. In addition, NTA calculates
particle concentration. Both Ad and SiAd were measured using Malvern Nanosight
(Figure 2.16A & 2.16B). Samples were diluted to 1 mL and five acquisitions at 30
seconds each were taken. The average size of Ad was 205.4± 5.7 nm, the mode size
was 122.3±1.3 nm, and the estimated concentration was 2.09 x 109 particles/ml. The
stock Ad solution itself contains aggregates of viruses even after vortexing and bath
sonication. The bimodal distribution in Figure 2.15A revealed a majority of particles
were around 100 nm (i.e. single virions) and another minor peak closer to 200nm that
are likley aggregates of two virions. For SiAd, the average size was 215.2± 7.0 nm,
Figure 2.16: (A) NTA of Ad stock. (B) NTA of SiAd. (C) Zeta potential of Ad,
Ad+PLL, and SiAd.
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the mode size was 141.3± 12.1 nm and the estimated concentration was 5.24 x 108
particles/ml. As expected the size of Ad increases post encapsulation (Figure 2.16B).
Since the stock solution of Ad serves as a template for silica condensation, aggregates
of virions will lead to larger silica particles (Figure 2.16B). This is corroborated by the
reduction in particle concentration with the assumption that there is minimal loss of
virions during the encapsulation process. As previously mentioned, the supernatant
from SiAd was tested for viral transduction and no significant transduction was found
though not completely negative at 1% of cells being GFP positive (Figure 2.13).
Under the assumption that a GFP positive cell was transduced by a single virion
then 1% of 100,000 cells results in only 1000 viral particles lost in the supernatant. If
the MOI factor is accounted for then there was potentially 50,000 viral particles lost
in the supernatant. Ultracentrifugation is one method to ensure complete collection
of the sample, but was not tested here. Overall, the NTA data revealed SiAd particles
that were slightly larger than Ad alone.
Another method used to characterize nanoparticles is measure the charge
as zeta potential. Zeta potential is a bulk measurement that takes into account all
charged species in solution and their interaction with the stern double layer of charged
particles. This measurement is performed in deionized water as buffered saline or any
ionic solution will corrode the electrodes of the device. Attempted zeta measurements
of Ad in PBS resulted in burnt electrodes and erroneous measurements. As reported
in the literature Ad has a native negative overall charge. Ad purchased from Vector
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Biolabs (Malvern, PA) is stored in DMEM with 2% bovine serum albumin (BSA) &
2.5% glycerol. Glycerol is added to impart stability through freeze thaw cycles and is
a common additive to viral stock solutions. The zeta potential of Ad stock solution
diluted 100 fold in DI water was−35.9±0.8mV as measured using Malvern’s Zetasizer
instrument (Figure 2.16C). The presence of BSA and glycerol likely effect both the
surface charge and subsequent silica deposition. BSA has an overall negative charge
at pH 7 and thus can act as a silica deposition site. The zeta potential of just Ad
incubated with PLL before silica deposition was measured at −17± 0.6mV (Figure
2.16C). As expected PLL makes the Ad surface more positive relative to the native
Ad capsid. This also suggests that the surface could be made more positive. The
zeta potential of SiAd was measured at −27 ± 0.9mV (Figure 2.16C). As expected
the surface becomes more negative post silica encapsulation. The terminal hydroxyl
groups of silica contribute to its overall negative charge. In general, the negative
charge of silica templated nanoparticles confirms silica deposition onto the positively
charged template. In addition, anionic particles reduce the formation of a protein
corona associated with serum proteins depositing on cationic surfaces.
2.3.3 qPCR to Detect SiAd
Quantitative polymerase chain reaction (qPCR) is a standard analytical tech-
nique for detecting and measuring viral DNA in samples. This is based off of ampli-
fication of known target DNA using a designed primer sequence. We tested the use
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of qPCR to determine encapsulation efficiency of Ad. The target gene was 3’- GCA
CTC CAT TTT CGT CAA ATC TTA TAA TAA GAT GAG CAC TTT GAA CTG
TTC CAG ATA TTG GAG CCA AAC TGC CTT TAA CAG CCA -5’, which is the
fiber region of the Ad genome. A plasmid was selected and amplified against this
sequence and used to make a standard curve. Primers were designed using Primer-
BLAST (NCBI). All calculations were based of a standard curve derived from serial
dilutions of Ad plasmid and measured for each experiment. The cycle threshold
(Ct) value is a measure of how much DNA is present. Higher Ct values equate to
less DNA amplified and here translated to less virus present. All samples were run
in duplicate. qPCR was used to test the robustness of silica encapsulation and if
Figure 2.17: As expected qPCR of Ad (black) and plasmid dilutions (light blue)
amplified. Interestingly, SiAd (red) did not amplify.
Ad could be quantified post encapsulation. First, Ad and SiAd were tested and we
found that Ad amplified as expected, but SiAd did not amplify, a Ct value greater
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than 27 (Figure 2.17). This suggested that silica does provide a robust coating of
Ad. The first step in qPCR is a ramp to 90◦C for 2 minutes, which denatures all
hydrogen bonds between DNA base pairs to allow for primer annealing. As SiAd
did not amplify, this also suggests that the silica coat is robust enough to withstand
such heat treatment.
Next, probe sonication was used to further test the properties of silica. Others
in our lab have used probe sonication to break open HMSNs thus it was hypothesized
that probe sonication of SiAd could break open the silica coat and allow for viral
detection. SiAd was diluted in PBS and treated with various pulse sequences and
time using a QSonica Q125 sonicator. The instrument calculates a energy output for
each run, measured in joules. These samples were then processed with a Qiagen DNA
extraction kit and run on qPCR. Similar to previous experiments, SiAd amplified
at a average Ct = 27.8. When treated at 600 J the Ct decreased to 23 suggesting
that probe sonication was breaking SiAd and allowing DNA extraction. Each Ct
represents a two fold increase in DNA. Other energy outputs were tested on SiAd:
Ct = 24.6 at 2743 J, Ct = 26.8 at 5688 J, Ct = 26 at 140 J and Ct = 26 at 8037
J. Surprisingly, higher energy outputs resulted in less DNA extracted, likely due to
damaged DNA. Overall, probe sonication was not a reproducible and reliable method
for detecting SiAd via qPCR.
To test if silica itself was inhibitory to qPCR analysis, SiAd was spiked into
plasmid dilutions to see if there would be an affect on Ct value. Plasmid dilutions
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-4, -5, -6, and -7 had Ct values of 15.6, 18.5, 21.8, and 25.6, respectively. Plasmid
dilutions spiked with SiAd had Ct values of 16, 18.8, 21.6, and 23.1, respectively.
The only sample that was significantly affected was the -7 plasmid dilution, which
had a lower Ct. This is counter to other qPCR experiments and likely error. Though
on average this suggests that SiAd is not inhibitory to qPCR amplification.
Another method was tested to be able to quantify SiAd with qPCR. Previous
experiments showed that SiAd contained functional virions (Figure 2.14), which im-
plied that SiAd nanoparticles are endocytosed and follow a similar pathway as Ad.
During endosmal uptake, endosomal vesicles acidify. It was hypothesized that this
process dissolves the silica coat and release functional viral particles. Lactic acid was
tested to mimic this process ex vivo. If the silica coating could be removed with acid
treatment then qPCR would likely be able to detect Ad DNA. SiAd was treated with
Figure 2.18: Neat plasmid dilutions treated with lactic acid dilutions resulted in
variable Cts.
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lactic acid or HCl at 37◦C for 1.5 hours, subsequently extracted using a Qiagen kit,
and run on qPCR. SiAd untreated did not amplify (no Ct), SiAd treated with 0.02M
lactic acid had a Ct = 23.3, SiAd treated with 1.21 mM HCl had a Ct = 24.4 and
SiAd treated with 0.121 µM HCl had a Ct = 24.7. Lactic acid treatment resulted
in detectable DNA from SiAd, but it was suggested that residual acid would affect
downstream amplification. Thus plasmid dilutions were tested with acid treatment
and it was found that almost all acid concentrations changed the Ct value for plas-
mid standards (Figure 2.18). Due to this finding, quantification of SiAd via qPCR
was abandoned. Overall, SiAd samples with background or non-detectable Ct values
were considered samples with particles that were effectively encapsulated in silica.
2.4 In Vitro Data
2.4.1 Expanded Tropism and Enhanced Transduction
Viral tropism is parameter defined through evolution where virions transduce
specific cells using cellular surface receptors. In the case of Ad, virions interact with
the coxsackie-adenovirus receptor (CAR) and cellular integrins for cellular uptake.
CAR expression is variable among cell types and within tumors (see section 1.5.1).
With optimized SiAd particles (Figure 2.13), characterization and behaviour of such
particles was explored in vitro using various cell lines. For all experiments, flow
cytometry (FACS) was used to quantitatively measure GFP fluorescence and con-
focal microscopy was used to qualitatively visualize cells 48 hours after seeding Ad
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or SiAd at various MOIs. Geometric mean fluorescence is reported to reduce skew
associated with super bright cells and is measured on the total cell population not
just GFP positive cells. Note that absolute fluorescent protein expression cannot
be compared between cell lines due to differences in DNA transcription and DNA
translation. Mentioned previously, A549 was used as a positive control cell line since
Ad easily transduces these cells and is reported as CAR positive [6]. HeLa (human
cervix adenocarcinoma) is another common cell line that is reported as CAR posi-
tive [7]. Conversely, T98G (human glioblastoma multiforme), MCF7 (human breast
adenocarcinoma), CHO-K1 (Chinese hamster ovary) are inefficiently transduced by
Ad are reported as having low CAR expression [8], [9]. CHO-K1 being a non-human
cell line is ostensibly CAR negative. As expected both Ad and SiAd transduce in
a dose dependent manner. Across all MOIs, SiAd enhanced transduction on A549,
T98G, CHO-K1 and MCF7 (Figure 2.19 & Figure 2.20). This is most apparent at
MOI 50 where SiAd increased transduction, measured as total GFP fluorescence, by
3.9 fold for A549, 35.6 fold for T98G, 7.6 fold for CHO-K1, 14 fold for MCF-7. On
HeLa, only at MOI 50 did SiAd enhance transduction, by 1.6 fold, which suggests
that this cell line is strongly CAR positive (Figure 2.19). Clinical MOIs are less
the MOI 10 and likely closer to 1 or less depending on tumor volume and dosage.
FACS histograms showed a clear shift and increase in GFP positive cells with SiAd
treatment even at an MOI 10 (Figure 2.19B). Confocal images confirmed this finding
(Figure 2.19C). Enhanced transduction of fluorescent proteins serves as a proxy for
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Figure 2.19: (A) Transduction measured by FACS for A549, T98G, and CHO-K1.
(B) FACS histograms at MOI 10. (C) Confocal images showing transduction.
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enhanced delivery of any protein of interest and even enhanced production of viral
progeny.
Figure 2.20: Transduction measured by FACS for MCF7 and HeLa.
To test if enhanced transduction in a dish was due to particle settling, trans-
duction was tested on cell lines comparing dishes placed on a orbital shaker versus
dishes statically placed in an incubator. Across three cell lines (HeLa, CHO-K1, and
SKOV3) transduction was reduced 1.45 fold for Ad and 1.43 fold for SiAd, based off
geometric mean fluorescence. This suggests that particle settling is also a factor that
enhances transduction for Ad.
2.4.2 Co-tansduction with SiAd
First, to confirm that enhanced transduction with SiAd is not an aberration
of GFP, Ad-RFP (cat.#1660) or Ad-mcherry (cat.#1767) was tested. As expected
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SiAd enhanced transduction though both red fluorescent proteins tested are not as
bright or efficiently produced by cells. For example, at the same MOI there are
more GFP positive cells than cells positive for RFP or mCherry. Both NTA and
TEM data revealed a population of particles that likely contained multiple virions
(size ∼200 - 400 nm). A mixing experiment was devised that used two different
virions, Ad-GFP and Ad-RFP, to test if SiAd particles could contain both viruses.
Equal parts of Ad-GFP and Ad-RFP were mixed. One aliquot was used for Ad
control and another aliquot was used to make Si(Ad-GFP + Ad-RFP). In addition,
SiAd made only with Ad-GFP or only with Ad-RFP and then mixed was tested.
Confocal microscopy revealed that cells transduced with Si(Ad-GFP + Ad-RFP)
Figure 2.21: Transduction of Ad-RFP + Ad-GFP, SiAd-GFP + SiAd-RFP, and
Si(Ad-GFP + Ad-RFP). Cells that expressed both colors (yellow) were transduced
with both viruses. Performed in duplicate.
showed significantly more cells expressing both GFP and RFP, cells appear yellow,
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as compared to mixing of SiAd-GFP and SiAd-RFP or compared to Ad mixture
(Figure 2.21). If SiAd particles only contained one type of virus then there would
have been no difference between Si(Ad-GFP + Ad-RFP) and SiAd-GFP + SiAd-
RFP transduction.
Figure 2.22: Transduction of Ad-RFP + Ad-GFP, SiAd-GFP + SiAd-RFP, and
Si(Ad-GFP + Ad-RFP) as measured using flow cytometry on T98G cells.
This was confirmed using T98G cells at both MOI 10 and 50 and measured
using flow cytometry (Figure 2.22). Again, we saw enhanced co-transduction of cells
with Si(Ad-GFP + Ad-RFP) at both MOIs. At MOI 10, both Ad-R/G and SiAd-R
+ SiAd-G showed similar levels of co-transduction at 3.3% and 2.8%, respectively,
but Si(Ad-R + Ad-G) had 10.6% co-transduction. At MOI 50, Ad-R/G only co-
transduced 9.8% of cell but SiAd-R + SiAd-G and Si(Ad-R + Ad-G) showed similar
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high levels of co-transduction at 51.1% and 57.8%, respectively. Quadrant 2 (Q2) on
the FACS plots corresponds to cells expressing both eGFP (G) and mCherry (R).
Enhanced co-transduction of two fluorescent proteins serves as a proxy for any two
therapeutic genes of interest.
2.4.3 Live Cell Imaging
Live cell imaging (Nikon A1R STORM) was performed to study kinetics of
transduction between Ad and SiAd at MOI 50 over 12 hours. A549 and MCF7 cells
were plated in a six well plate that had a coverslip bottom (6-well No. 1.5 coverslip,
Mattek Corporation). Confocal images were taken at 15 minute intervals for a 12
hour period. Since protein expression follows transduction, imaging was started four
hours (240 minutes) post-addition of particles. As expected and consistent with
previous data, SiAd enhanced transduction on both A549 and MCF7 (Figure 2.23A
& B). Cutouts show a zoomed in view of the first 300 minutes and revealed that
for the first 440 minutes Ad fluorescence is greater than SiAd. For cells treated
with SiAd there was a marked increase in fluorescence between 440-540 minutes
post-transduction. This delay can be attributed to differences in receptor mediated
endocytosis of Ad versus non-specific uptake mechanisms for SiAd. It is surmised
that there is also a delay due to dissolution of the silica coat within the cell and
subsequent viral release, which is reflected in this initial delay.
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Figure 2.23: GFP intensity over 12 hour period on (A) A549 and (B) MCF7
transduced with Ad or SiAd.
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2.4.4 Cell Line CAR Expression
Western blotting was used to measure cellular CAR expression as CAR ex-
pression is variable between cell lines. Cell lysates were normalized using a Bradford
assay and run on a SDS-Page gel (Bio-Rad). Protein was then transferred and
probed with either Anti-CAR (Santa Cruz Biotechnology) or Anti-CAR (Cell Sig-
naling Technology). Bands were visualized using horseradish peroxidase secondary
antibody. Actin was used as a positive control for all blots. We found that both
antibodies used to probe for CAR resulted in smearing of bands and potential non-
specific binding. Interestingly, MCF7 showed the strongest level of CAR expression
by western blot (Figure 2.24A), which is in contrast to the relatively lower levels of
Ad transduction observed. Chinese Hamster Ovary cells (CHO-K1) are ostensibly
human CAR negative and thus should be negative for CAR expression, but showed
bands for CAR (Figure 2.24b). From these results, we determined that western blot
was a poor technique for determining CAR expression using the antibodies available
for purchase. CAR expression can be extrapolated from the efficiency of neat Ad
transduction.
2.4.5 Endosome Acidification and Trafficking
Endosomes and their derivatives play an important role in cellular uptake and
intracellular release of all types of particles [10]. Viral uptake and release mechanisms
are well understood, but synthetic particle trafficking is relatively a black box and
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Figure 2.24: (A) Western blot using Santa Cruz Anti-CAR and (B) probed with
Cell Signaling Anti-CAR on cancerl cell lines.
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dependent on particle surface charge, size, shape, and material of choice. Silica is
known to dissolve in both acidic and basic conditions. This is an important attribute
for SiAd’s function. To investigate this, we used chloroquine phosphate (CP) to
inhibit endosome acidification on A549 cells. Deprotonated CP can easily diffuse
across cellular membranes and into endosomes where it quickly becomes protonated
and trapped; thus, acting as a proton sink [11]. CP is a drug traditionally used to
inhibit pH-dependent processes in malarial infections and has also been explored as a
anti-HIV treatment [12]. A549 cells were plated overnight. The media was removed
and replaced with 2.32M chloroquine phosphate (Sigma Aldrich) made in FBS free
media. The cells were incubated for one hour with CP treated media, washed with
PBS, and subsequently transduced at MOI 50 in standard media. Geometric mean
fluorescence measured by FACS was used to determine the effect of CP. We found
that post CP treatment, SiAd transduction reduced by 73.8% while Ad transduction
was reduced by 19.3% (Figure 2.25A). We found that endosome acidification was
more important for SiAd transduction and a critical step for function. Blocking of
endosome acidification likely prevents the dissolution of the silica coat and subsequent
viral release leading to reduced transduction. Initially virologists believed that Ad
disassembly was also a pH dependent process that occurred in late endosomes, but
recently it has been shown that disassembly may take place near the cell membrane
and therefore makes Ad less sensitive to inhibition of endosome acidification [13].
To further investigate endosomal trafficking of particles we employed the use
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Figure 2.25: (A) Inhibition of endosome acidification on A549 using chloroquine
phosphate (CP) significantly reduces SiAd transduction. (B) Transduction of HAP
deficient in Rab4A, Rab5A or Rab7a. GFP intensity normalized to wild type (WT)
in each group. (C) Number of GFP positive cells normalized to WT in each group.
Statistical comparison done with respect to WT. ∗P ≤ 0.1, ∗ ∗ P ≤ 0.01, ∗ ∗ ∗P ≤
0.001, ∗ ∗ ∗ ∗ P ≤ 000.1
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of modified haploid cells (HAP) deficient in Rab4A, Rab5A and Rab7A proteins,
which are implicated in endosome recycling, early formation, and transition to late
endosomes, respectively [14], [15]. There are numerous Rab proteins involved in
the complex exchange of intracellular vesicles. These modified cells help elucidate
trafficking mechanisms, but biology has redundant mechanisms and generally cells
deficient in a single protein are too simplistic a model. HAP cells were generated by
Horizon Discovery via CRISPR-Cas9 knockout and maintained in Iscove’s Modified
Dulbecco’s Medium. Cells were transduced at a MOI 10 and the number of GFP
positive cells was counted at 48 hours using ImageJ software. As only endocytosis
of one virion can lead to GFP production, the number of GFP positive cells was
analyzed. Examining the GFP fluorescence did not reveal any significant differences
(Figure 2.25B). Experiments are normalized to wild type HAP cells. For both Ad and
SiAd, there was an increase in the number transduced cells in the Rab4a and Rab7a
knock out cell lines (Figure 2.25C). As expected, endosome recycling and formation
of late endosomes are pathways that limit viral release and function. These results
suggest that SiAd follows a similar endosomal trafficking pathway as Ad and supports
the finding that SiAd particles contain viable, functional virions.
Next, we attempted to determine if CAR had any direct effect on SiAd up-
take. It is clear that SiAd can transduce across many cell lines and ones that have
low CAR expression (see Figure 2.19), but was not definitive if this property was
independent of CAR expression. To determine this, ideally, a cell line that tradi-
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Figure 2.26: Transaction was tested on cells treated with Anti-CAR antibody,
∗P ≤ 0.1
tionally expresses CAR could be genetically modified via CRISPR or other gene
editing tools to not express CAR, a CAR knock out. An easier and cheaper method
of achieving something similar is to use an antibody against the receptor to block
it. Anti-CAR was purchased against the extracellular domain (E1-1, Santa Cruz
Biotechnology). Serial dilutions of antibody were tested with Ad to determine the
effective concentration, which was the concentration of the stock solution. A549 cells
were plated overnight and subsequently incubated with 1:10 dilution of Anti-CAR in
FBS free media for three hours. Media was then replaced with standard media and
cells were transduced at MOI 1. We observed only a slight change in Ad tansduc-
tion of Anti-CAR treated cells and no difference in SiAd transduction (Figure 2.26).
Antibodies are notoriously variable from company to company and we expected a
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larger decrease in Ad tansduction. CAR is the primary receptor used by Ad and
aided by cellular integrins, but there are secondary receptors such as heparan sulfate
glycosaminoglycans that can also lead to transduction though with lower binding
affinity [16].
Experiments were attempted to parse out cellular uptake of Ad or SiAd using
the inhibitors: chlorpromazine (clathrin-mediated endocytosis inhibitor), genistein
(caveolae-mediated endocytosis inhibitor), or amiloride (macropinocytosis-mediated
endocytosis inhibitor), but were unsuccessful.
2.4.6 Silica Bio-compatibility
Silica dioxide, silica, is a FDA approved food additive and has been tested in
many biomedical applications [17]. To confirm that SiAd was biocompatible in vitro,
we used a simple MTT assay to look for cell viability. This assay technically tests cell
metabolic activity where the MTT reagent is reduced to formazan in metabolically
active cells and is detectable by a colomertric assay. Non-metabolically active cells
are assumed to be dead or dying from treatment toxicity. No toxicity was detected
for either Ad or SiAd up to a MOI 1000 (Figure 2.27). Triton-x was used as a positive
control to ensure the assay was able to detect cell death.
2.4.7 Antibody Neutralization
There are 51 serotypes of Ad that can infect humans which leads to the
large population, estimated between 45 to 80%, of people (potential patients of gene
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Figure 2.27: MTT assay on serial dilutions of Ad and SiAd. 3% Triton-x was used
as a positive control.
therapy) that have neutralizing antibodies already in their system [18]. These neu-
tralizing antibodies reduce the efficacy of Ad based treatments. We hypothesized
that coating of Ad could mask antigen recognition in the presence of such neutral-
izing antibodies. The hexon protein is the major constituent of the capsid and the
majority of antibodies are generated against it. Thus we tested transduction of Ad
and SiAd with serial dilution of anti-hexon spiked into the culture media. Unfortu-
nately we found that SiAd had reduced transduction in the presence of anti-hexon
antibodies (Figure 2.28A). To test if this was due to nonspecific binding, we first
tried blocking the surface of SiAd with human albumin. This alone reduced trans-
duction, but not for naked Ad, supporting that surface charge was an important
factor (Figure 2.28B). This is surprising since fetal bovine serum (FBS) is used to
make cell culture media and a major component of FBS is bovine serum albumin
(BSA). Traditionally, polyethylene glycol (PEG) is used to increase circulation half-
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life of proteins and nanoparticles by creating a hydration layer that ”shields” the
particle. This modification improves pharmacokinetics, but changes how these par-
ticles engage the cell surface. Cell surface interaction is an important step for Ad
transaction to occur thus pegylation reduces transduction [19]. Using PEG-silane
to modify SiAd further ablated transduction, as expected (Figure 2.28B). This non-
Figure 2.28: (A) Transduction in the presence of anti-hexon. (B) Effect of albumin,
PEG, anti-hexon.
specific binding phenomenon was tested with other antibodies such as human IgG
and mouse IgG and it was observed that transduction was reduced. One factor that
should be considered is that in vitro concentrations of antibodies are likely much
higher than found in blood. Overall these experiments suggest that the silica layer
is sticky and potentially can adsorb serum proteins.
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2.4.8 Co-delivery with Cetuximab
This sticky or nonspecific binding nature of the silica layer was at first viewed
as serious downfall, but we tested to see if we could use it to our advantage. Anti-
bodies can be used as stand alone drugs or as targeting moieties for nanoparticles.
Targeting of nanoparticles using a small molecule or antibody is way to increase
specificity and reduce off target effects. These targeting molecules are chosen based
off over expression profiles of the cancer of interest [20]. Cetuximab is a FDA ap-
proved chimeric antibody to the epidermal growth factor receptor (EGFR) that is
over expressed in many epithelial cancers [21]. To test if SiAd’s nonspecific up-
take of antibodies could be used for targeting, we premixed Cetuximab with SiAd
or Ad at multiple concentrations and tested transduction on EGFR positive A549.
In addition, these formulations were tested in the presence of anti-Ad antibodies
to determine if Cetuximab could act as a blocking agent. We found that addition
of Cetuximab only slightly increased transduction, though non-significant, and that
pre-mixing with Cetuximab did not prevent neutralization by Ad antibodies (Figure
2.29). Effect of PLL chain length was discussed previously.
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Figure 2.29: Transduction with Anti-EGFR and/or in the presence of Anti-Ad
antibodies. Particles were also synthesized with 70-150k PLL (150k) and 30-70k
PLL (70k).
2.4.9 Particle Stability
Nanoparticle stability is an important factor to consider for large-scale pro-
duction and manufacturing. In general, viruses are stable when stored frozen at
-80◦C and it is well known that viral efficacy decreases after multiple freeze-thaw
cycles. We found that viral preparations made with sequential cesium-chloride pu-
rification significantly lose activity after a single freeze-thaw cycle (see Figure 3.8).
Viral stocks that are stored in buffers containing media and glycerol were found to
be stable over multiple freeze-thaw cycles. To test SiAd stability and function, for-
mulations were split and either stored at -80◦C or 4◦C for seven days. Transduction
was tested on A549 cells and compared against fresh preparations (Figure 2.30). We
found that for SiAd formulations, transduction was reduced under both storage con-
ditions. This is likely due to unreacted free silicic acid present in solution or from
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Figure 2.30: Effect of storage conditions on transduction.
freeze-thaw physically breaking SiAd particles. For all experiments both fresh Ad
and SiAd were made and used the same day. Further experiments need performed
to improve SiAd stability. Dielectrophoresis is one method that could be used to
separate unreacted silicic acid from particles in solution.
2.4.10 Enhanced CAS9 Expression
To test delivery of an actual protein of interest, we purchased Ad-eGFP-
Cas9 (Vector Biolabs cat.#1901) and tested transduction. This vector is designed
to produce the Cas9 protein along with a GFP reporter. Cas9 is a endonuclease
used for guide RNA directed cutting of DNA and is the basis for CRISPR-Cas9
gene editing [22]. As expected we saw enhanced transduction of cells with SiAd as
measured using the GFP reporter that correlates with Cas9 expression. Future work
seeks to use enhanced Cas9 expression to improve the efficiency of gene editing using
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this technique.
2.5 Summary and Future Directions
We developed a technique that encapsulates adenovirus in silica as a nanopar-
ticle formulation. Using nanoparticle characterization techniques we showed SiAd
nanoparticles that are slightly larger than neat Ad and that can be visualized using
TEM. The synthesis reaction was optimized to produce particles that significantly
enhance transduction of cancer cell lines, which have varying degrees of Ad trans-
duction efficiency i.e. coxsackie-adenovirus receptor expression. Expanded tropism
using SiAd overcomes the long evolutionary history of Ad, which is dependent on
CAR binding. Mixing experiments with two viruses (GFP & mCherry) supported
both the NTA and TEM data that suggested that SiAd formulations had a popula-
tion of particles containing more than individual virions. This opens up the potential
to combine multiple virions that have synergistic therapeutic genes to be delivered
to any cell of interest. The endosome is an important cellular compartment that
controls internalization and release of foreign objects i.e. viruses and nanoparti-
cles. We found that endosome acidification is a critical step for silica dissolution
and SiAd function. In addition, using cell lines deficient in Rab proteins we found
the SiAd and Ad particles follow similar endosomal trafficking pathways supporting
hypothesis that SiAd contains functional virions. Overall, these experiments show
that SiAd can enhance transduction of many cells in vitro and could be applicable
92
to ex vivo therapies that modify cells in a dish. Fluorescent protein expression is
a proxy for viral replication and the expression of any protein, shRNA, or cytokine
of interest. Thus enhanced delivery of Ad is important not only for oncolytic viral
therapy, but also for other gene delivery applications. This technique could also be
Figure 2.31: Enhanced transduction of retroviruses (Rtv) with SiAd synthesis pro-
cedure.
applied to other viruses, specifically the enveloped viruses: retrovirus and lentivirus,
which integrate their genomic information resulting in permanent transgene expres-
sion. These viruses are commonly used in chimeric antigen receptor T-cell therapy
where T-cells are modified ex vivo and re-administered to the patient. Preliminary
experiments showed enhanced transduction of retroviruses (Rtv) on A549 cells using
the same procedure as SiAd synthesis (Figure 2.31). Further characterization and
optimization of SiRtv needs to be explored.
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Chapter 3
Biodistribution and Immune Response to
SiAd in Immune-compromised and
Immune-competent Mice
It is well known that biomedical technologies from pharmaceuticals to nanopar-
ticles behave differently in an dish than in an animal model. This stems both from
the complexity of biological systems and the relatively simplistic in vitro experi-
mental setups. A major factor in vivo that influences viral and nanoparticle fate is
pharmacokinetics, which relates to the distribution, bioavailability, absorption, ex-
cretion, and metabolism of drugs/viruses/nanoparticles. This is largely influenced
by the method of delivery, particle size, particle charge, and particle shape [1], [2].
This is further complicated by the choice of animal model. Here we tested Ad and
SiAd in both immune compromised (NOD scid gamma) and immune competent
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(C57BL/6) mice. All animal experiments were approved by the Institutional Animal
Care and Use Committee (IACUC) and the Institutional Biosafety Committee (IBC)
at Oregon Health and Science University (Portland, OR). In NSG mice, we generated
xenografts from the T98G cell line, which showed high levels of SiAd transduction in
vitro. First, we tested the biodistributiong of SiAd using luciferase (luc) as a reporter
gene. Then as a model for cancer gene therapy we used Ad expressing TNF-related
apoptosis-inducing ligand (TRAIL) that selectively induces apoptosis in cancer cells.
In immune competent mice we tested luc expression in muscle via IM injections and
measured plasma cytokine levels as a measure of the innate immune response to Ad
or SiAd. In addition, to look for the adaptive immune response we measured plasma
neutralizing antibodies. Overall the in vivo data makes a strong case for enhanced
cancer gene therapy using SiAd.
3.1 Immune Compromised Model
3.1.1 T98G Xenografts
Generation of tumor xenografts, human cells in a animal model, is a common
technique to mimic human solid tumors at a basic level. In general, xenografts can
only be grown in immune compromised animals of which the easiest to work with are
mice. As the T98G cell line showed robust transduction in vitro, we generated T98G
xenografts in NOD scid gamma (NSG) mice. NSG mice were purchased from the
Jackson Laboratory (stock #005557). Mice were housed in high-efficiency particulate
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air (HEPA) cages in a specific pathogen-free facility with food and water available
ad libitum and a 12-hour light/dark cycle. Both male and female mice were used for
the experiments, aged between 8-12 weeks. Xenografts were formed by subcutaneous
injection of 200µl into both flanks with 2x106 T98G cells (ATCC) in a 1:1 ratio of
DMEM:Matrigel HC (Corning) containing 0.5µg/mL recombinant human Vascular
Endothelial Growth Factor (VEGF) (R&D Systems) and 1.25µg/mL recombinant
human Fibroblast Growth Factor basic (FGF) (R&D Systems). Xenografts were
serially passaged by digesting the xenografts with Collagenase/Dispase (Roche) and
re-injecting the digested cells subcutaneously in the same solution as performed ini-
tially. Xenografts were ≤1cm3 at the time of injection. The first set of tumors took
almost three months to grow, but subsequent passages reduced this time to a few
weeks.
3.1.2 Intratumoral Injections
We tested Ad expressing luciferase (Ad-luc) purchased from Vector Biolabs
(Malvern, PA) at two different concentrations and preparations. The first prepara-
tion was one that is commonly used for in vitro experiments at 1x1010 PFU/ml in
a crude buffer of DMEM, 2% BSA, 2.5% glycerol. This preparation is similar to
the Ad-GFP prep used for all experiments in Chapter 2. A second preparation was
also tested, designed for in vivo work that was purified with two sequential cesium
chloride gradients at 1x1011 PFU/ml and stored in 5% glycerol in PBS. Note that
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luciferase is a common reporter gene derived from fireflies that produces biolumi-
nescense through the enzymatic breakdown of the substrate luciferin. For imaging,
100uL (3mg, 150mg/kg) of VivoGlo Luciferin (Promega) was injected intraperi-
toneally into mice 9 minutes prior to initial imaging. Mice were anesthetized with
isoflurane and then imaged in the IVIS Lumina XRMS Series III (Perkin Elmer).
For each mouse both the abdomen and back were imaged with the same settings:
5-minute exposure, medium binning, and F-stop = 1. Mice were imaged a single
time per day, but multiple times over the course of an experiment. Unless spec-
ified, luciferase expression 5 days post treatment, measured as average radiance
(p/s/cm2/sr), is reported. Average radiance was determined using Living Image
Software (Perkin-Elmer) at a 25% threshold. When tumors or livers did not show
measurable levels of luciferase, a default area was used to calculate signal intensity
and was consistent between experiments.
First, we tested low dose Ad-luc (1x1010 PFU/ml) on T98G xenografts. SiAd
was made as outlined in Chapter 2. Tumors were injected with 50µl of Ad or SiAd
(5x107 PFU). Each mouse received two IT injections of a single treatment and was
imaged at day 5. Representative images shown in Figure 3.1A. We found that the
average radiance for tumors injected with Ad and SiAd was 9.83x104± 1.94x105 and
2.75x105± 4.54x105, respectfully, though non-significant (Figure 3.1B). On the other
hand, we found that liver transduction was significantly reduced in mice treated
with SiAd where the majority of mice had background levels of liver luciferase signal
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(Figure 3.1B). In line with previous studies, liver transduction in Ad treatment mice
was very robust at 4.44x105± 1.36x105, which is higher than Ad tumor transduction
itself. This is most obvious when comparing the total tumor transduction to liver
signal in each mouse where SiAd treated mice had on average significantly reduced
off-target transduction by 272 fold (Figure 3.1C). To confirm this finding, we IT
injected one tumor with SiAd-GFP and Ad-mCherry and looked for transduction
in tumor and liver sections (Figure 3.1D & E). Tumor sections showed comparable
levels of SiAd and Ad transduction, however liver sections showed markedly reduced
SiAd transduction (green) vs. Ad (red). This data is derived from two separate
experiments on passage 2 and passage 3 of tumors.
Considering that 1 cm3 of tumor tissue contains 1x108 - 1x109 cells and that
these initial experiments were done with 5x107 PFU, this resulted in an MOI less
than 0.5-0.05 [3]. This is a very low dose of viral particles compared to in vitro
experiments where typical MOIs range between 5 and 500. To increase the dose, we
purchased Ad-luc (Vector Biolabs) at 1x1011 PFU/ml. SiAd particles were made
under the same conditions as low does particles, though with 10x the concentration
of virions [i.e. 5µl of 1x1011 PFU/ml was incubated with 1.5µl of 0.1% PLL for 15
minutes then 1µl of silicic acid (1.8µl TMOS + 48.2µl 1mM HCl) was added and the
total volume was diluted to 30µl in 0.05x PBS]. Note that the high dose preparation
is considered to be more pure than the low dose preparation as viruses are stored in
5% glycerol in PBS.
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Figure 3.1: T98G xenografts were treated with either Ad (n=5) or SiAd-luc (n=6)
at 5x107 PFU. (A) Representative IVIS images showing comparable levels of tumor
transduction, but reduced liver expression when treated with SiAd. (B) Average
radiance of tumors and livers. (C) Comparison of total tumors expression to liver
transduction.**p≤0.005, ONE-way ANOVA, Kruskal-Wallis. Data reported as mean
± STD. (D) Tumor section injected with SiAd-GFP and Ad-mCherry. (E) Liver
section from the same mouse as (D). Scale bars represent 200µm.
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Figure 3.2: T98G xenografts were treated with either Ad (n=5) or SiAd-luc (n=9)
at 5x118 PFU. (A) Average radiance of tumors and livers. (B) Comparison of total tu-
mor expression to liver transduction.**p≤0.005, ONE-way ANOVA, Kruskal-Wallis.
Data reported as mean ± STD.
We found that tumors treated with Ad had very poor transduction with an av-
erage radiance of 4.52x103± 4.70x103 whereas tumors treated with SiAd had 23-fold
enhanced transduction with an average radiance of 2.52x105± 4.65x105 (P=0.0094,
Kriskal-Wallis) (Figure 3.2A). The liver transduction followed a similar pattern to
low dose treatments where livers of Ad treated mice had an average transduction
of 6.09x105± 8.15x105 and livers of SiAd treated mice had reduced transduction at
9.02x104± 1.75x105. Again, when comparing the total tumor transduction to liver
transduction for each mouse we found SiAd treated mice had on average significantly
reduced off-target transduction by 165 fold (Figure 3.2B). This data is derived from
three separate experiments on passage 6, passage 7, and passage 10 of tumors. Sur-
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Figure 3.3: Comparison between transduction of tumors and livers with low dose
and high dose IT injections.
prisingly on the tenth tumor passage experiment, all five mice that were injected
with neat Ad asphyxiated within minutes of IT injections and had to be sacrificed.
This response is likely a result of the entire dose entering the circulation and caus-
ing an immediate immune reaction. We ruled out the possibility of a toxin in the
solution as SiAd particles were made using the same stock and reconstituted in the
same PBS.
When comparing the data from low dose and high dose experiments we can
find some interesting trends. First, the transduction of Ad tumors was reduced when
treated with high dose, but SiAd transduction was comparable between the two doses
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(Figure 3.3). This suggests that reduced Ad transduction is due to loss of CAR
expression through the serial passaging of tumors in vivo. Second, liver transduction
was slightly elevated in high dose SiAd treated mice suggesting that encapsulation
method may not cover all viral particles since the same coating procedure was used
for high dose preps as was used for low dose preparations. qPCR could potentially be
used to determine encapsulation efficiency when using high dose preparations since
encapsulated particles do not amplify on qPCR (see section 2.3.3).
Figure 3.4: Confocal images of Ad and SiAd transduction on passage #3 of T98G
xenografts, which was the last viable passage that could grow in vitro.
We observed that Ad tumor transduction reduced as we passaged tumors. In
addition, in the process of passaging tumors we tried growing an aliquot of cells in
vitro in a dish. After passage three, cells were no longer able to grow in a dish.
This suggested that cells had adapted to grow in NSG mice and possibly were losing
CAR expression through differentiation. This is similar to clinical findings that some
tumors have variable CAR expression dependent on tumor progression (see section
105
Figure 3.5: (F) Ad tumor transduction reduced over passage number. (G) Tumor
CAR expression dramatically reduced from P0 to P4.
1.5.1). We tested the in vitro transduction of passage #3 and found that Ad-mCherry
had very low transduction even at a MOI 50 (Figure 3.4).
This is further supported by looking at the tumor luciferase expression versus
tumor passage number (P#). Passage #3 and on had significantly lower Ad trans-
duction of tumors (P=0.02, ANOVA) whereas SiAd transduction was similar across
passage number (Figure 3.5F). To confirm that CAR expression was likely a factor
for this finding, we took tumor sections from the first set of xenografts (P0) and
from P4 and looked for CAR expression by immunofluorescence. Tumors sections
were stained primary CAR antibody (Bioss #bs-2389R, 1:100 dilution) and visual-
ized with alexa fluor 647 secondary antibody (1:400). We observed a clear difference
in CAR expression between P0 and P4 tumor sections (Figure 3.5G). This finding
supports the in vitro data showing expanded tropism across cell lines where CAR
expression is also variable and suggests that SiAd can transduce tumors independent
of tumor differentiation or progression and CAR expression.
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Figure 3.6: T98G xenografts were treated with either Ad or SiAd-luc at 5x117 PFU
or 5x118 PFU. (A) Average radiance of tumors and livers. (B) Comparison of total
tumor expression to liver transduction. *p≤0.05 **p≤0.005, ****p≤0.0001 ANOVA,
Kruskal-Wallis. Data reported as mean ± STD.
Compiling all the data from all experiments performed on T98G xenografts
using luciferase expression revealed that SiAd enhanced tumor transduction by 23-
fold (P=0.02, Kruskal-Wallis) and reduced off-target liver transduction by 210-fold
(p≤0.0001, Mann-Whitney t-test) (Figure 3.6A & 6B). Reduced liver transduction is
important to minimize hepatotoxicity assocaited with Kupffer cell uptake of virions
and downstream immune response. For oncolytic viral therapy or any gene therapy
method that does not seek to treat the liver, liver sequestration is considered a
sink for viral load. We found that SiAd improves the retention of particles at the
site of injection leading to both enhanced tumor transduction and reduced liver
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transduction.
3.1.3 Intramuscular Injections
To further study the biodistribution properties of SiAd, we tested intramus-
cular injections in NSG mice using a luciferase reporter. Mice were injected into
both hind limbs with 50µl of Ad or SiAd and luciferase expression was measured
as previously described. Surprisingly, SiAd muscle transduction was low compared
Figure 3.7: IM injections of 5x107 PFU of Ad or SiAd in NSG mice. (F) Ratio of
total muscle transduction to liver transduction for each mouse. (G) Average radiance
of muscles and livers over 25 days.
to Ad, which robustly transduced muscle. When looking at the ratio of muscle to
liver transduction (M/L), we found that SiAd had greater M/L for all time points
measured and that this ratio increased over time (Figure 3.7F). This is in contrast
to the M/L for Ad which remained, around 1, for all time points: days 5, 11, 15 and
25. This is clear when looking at the average radiance of muscles and livers over the
time course study. The luciferase signal of muscles injected with SiAd had a 10 fold
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increase between days 5 and 15 whereas the liver signals from these mice remained
constant (Figure 3.7G). Linear regression analysis showed that only the SiAd muscle
signal had significantly non-zero slope suggesting that in muscle, SiAd particles are
being slowly released at the site of injection, but not released into the bloodstream
which would result in liver transduction.
Figure 3.8: Comparing IM injections of 5x108 PFU of Ad or SiAd in NSG mice
from a vial stock that was had undergone a single freeze-thaw cycle (fresh) or one
that had been thawed, refrozen, and thawed again (refrozen). SiAd rescues lost Ad
activity.
We also tested the higher dose preparation in NSG mice. We found that mice
injected with Ad had background levels of luciferase signal, but mice injected with
SiAd had good signal. This is in contrast to the low dose data. For the first high dose
experiment we used a vial of Ad-luc that had undergone one re-freeze cycle at -80C. It
is known that Ad loses some activity from freeze thaw cycles and that Vector Biolabs
recommends to avoid multiple freeze-thaw cycles. Fresh Ad is considered stock that
109
Figure 3.9: IM injections of 5x108 PFU of fresh Ad or SiAd made from a vial stock
that had undergone a single freeze-thaw cycle in NSG mice.
was thawed at the time of use whereas refrozen Ad is considered stock that was
thawed, refrozen at -80C, and thawed again for use. We observed this phenomenon,
where muscles injected with refrozen Ad had background levels of luciferase signal
(Figure 3.8).This is clear when comparing both the muscle and liver transduction
of mice injected with either fresh Ad versus refrozen Ad (Figure 3.8). Interestingly,
muscles injected with SiAd had robust signal. In contrast SiAd made with either
fresh or refrozen Ad had comparable levels of both muscle and liver transduction
(Figure 3.8). In this case, silica encapsulation is acting as a transfection reagent
and suggests that the silica encapsulation procedure does coat all of the virions
present as unencapsulated viral particles would have lost activity after freeze-thaw.
Freeze thaw cycles effect the capsid protein structure leading to loss of transduction
efficiency for naked Ad, but when performing the silica reaction the PLL still covers
these aberrant capsids and allows for silica deposition. Thus, as long as the viral
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DNA can be delivered to a cell then protein expression is likely. We performed a
second experiment, where we IM injected fresh Ad and saw robust muscle and liver
signal, which was greater than SiAd made with refrozen Ad (Figure 3.9).
3.1.4 Intravascular Injections
Though SiAd particles are somewhat large for effective intravascular (IV)
delivery to tumors via the enhanced permeability and retention effect (EPR), we
tested IV injections in tumor free NSG mice. EPR is based off the finding that
growing solid tumors produce leaky vasculature where nanoparticles can passively
accumulate [4]. Out of curiosity we tail vein injected SiAd and measured luciferase
Figure 3.10: IV injections, tail vein, of 5x108 PFU SiAd (n=3) in NSG mice.
signal over 25 days (Figure 3.10). As expected, tails injected with SiAd had strong
signal. In two of the three mice, livers had comparable signal to tails and the liver of
the third mice had no signal. This data confirms the hypothesis that SiAd particles
111
are retained and tend to stay at the site of injection. The liver transduction is
attributed to SiAd particles that were cleared from the circulation.
3.1.5 Cancer Gene Therapy using TRAIL
To test the efficacy of delivering a therapeutic gene we purchased Ad ex-
pressing TNF-related apoptosis-inducing ligand (TRAIL) at both preparations, low
and high dose (Vector Biolabs, Malvern, PA). TRAIL is ligand that binds receptors
TRAIL-R1 and TRAIL-R2 and induces apoptosis through the death-inducing signal-
ing complex (DISC) and downstream induction of caspase-8 [5]. It has been reported
that TRAIL selectively induces apoptosis only in cancer cells and not healthy ones;
thus, serves a good model for cancer gene therapy.
First, to confirm that TRAIL was capable of killing T98G cells we tested Ad
and SiAd-TRAIL in vitro. Cells were treated with either Ad-TRAIL or SiAd-TRAIL
at a MOI of 10 and 50. After 48 hours cells were stained with propidium iodide,
which is a common intercalating dye which binds DNA and cannot cross live/intact
cell membranes, and measured using flow cytometry. Cells were measured using flow
cytometry and gated versus cells treated with PBS alone. At both MOI 10 and MOI
50, SiAd significantly killed more cells than Ad (Figure 3.11). Treated cells were also
smeared on a slide and visualized with confocal microscopy (Figure 3.11). Even at
a MOI 50, TRAIL induced apoptosis was inefficient with Ad-TRAIL killing only 8.5
±2.6% and SiAd-TRAIL killing 13.9 ±0.2% of cells.
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Figure 3.11: SiAd is significantly more potent than Ad in vitro. (A) T98G cells
were treated with Ad or SiAd-TRAIL at different MOIs, stained with propidium
iodide after 48hrs and measured using flow cytometry. (B) Stained cells visualized
on a glass slide.***p≤0.0005
Once confirmed that T98G cells were susceptible to TRAIL induced apoptosis,
we tested both low dose and high dose treatment on T98G xenografts. Xenografts
were injected at the smallest size possible and tumor volume was measured at day
0, 2, 5, 7, 9 and 11. In addition, we injected at multiple time points to increase
the effective dose of TRAIL and as is practiced in clinical trials. Tumor volume was
calculated by measuring two dimensions of a tumor using a caliper where the third
dimension is assumed to be the smaller of the two. Data is reported at % tumor
volume change for each tumor normalized to the tumor volume pre-treatment. Both
low dose and high dose treatment with SiAd significantly inhibited tumor growth
compared to Ad, untreated and tumors treated with SiAd-luc (Figure 3.12). It was
not surprising that tumor volume did not reduced in size or plateau since cell culture
experiments showed that delivery of TRAIL even at a high MOI of 50 resulted only
in 10% cell death. As mentioned previously, we are estimated to be delivering
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Figure 3.12: SiAd-TRAIL significantly inhibited tumor growth compared to con-
trols. (A) Change in tumor volume with treatment Ad or SiAd at 5x107 PFU. (B)
Change in tumor volume with treatments Ad, SiAd, or SiAd-luc at 5x108 PFU.
***p≤0.0001
around an MOI of 0.05-0.5 even with the higher dose preparation. In addition, we
tested SiAd-luc (expressing luciferase) as a control to prove that TRAIL was cause
of reduced tumor volume and not potential toxicity due to the silica coating.
To determine if multiple doses was effective, we performed a log-log transform
of the data and linear regression analysis. From the log-log transform it is clear
that all treatment groups have similar, non-significantly different, slopes, but the
intercepts are significantly different (Figure 3.13). This suggests that only the first
dose has an effect on reducing the overall tumor volume. This is due to the overall
low dose of virus delivered. In order to induce stagnation of tumor growth, we would
have to deliver a dose effective to kill at least 50% of the tumor cells present since
tumors grow in an exponential manner.
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Figure 3.13: Log-log transform of all the TRAIL data shows that treatments have
similar slopes, but are off-set from each other. This suggests that only the first dose
is effective in killing cells.
Overall, this data shows that silica encapsulation of Ad can enhanced cancer
gene therapy in vivo by transducing cells that have low CAR expression and by
retaining particles at the site of interest. The experiments described above were
performed on late passage T98G xenografts (P4, P5, and P8) which had reduced
CAR expression compared to the original T98G cells (Figure 3.5).
3.2 Immune-competent Mice
Innate and adaptive immune responses to virions are one of the primary
barriers to successful clinical outcomes. These responses occur on two different time
scales, first the innate response happens within hours of injection and then the adap-
tive response occurs over days-weeks time. To study the immune response to SiAd,
we used albino C57BL/6 (wild-type) mice purchased from Charles River (strain code
493).
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3.2.1 Cytokine Panel to Measure Innate Response
Mice were IM injected in both hind limbs with either Ad or SiAd expressing
luciferase at 5x108 PFU, high dose preparation. We choose IM injections because IM
delivery is a common approach in the clinic for gene therapy and serves as a proxy
for IT injections. For the first experiment, 5 mice each were injected with Ad or
SiAd. Blood was collected retro-orbitally a few days prior to injection (to measure
background levels of plasma cytokines), six hours after IM injection, and 5 days post-
injection. Blood was centrifuged at 5000g for 10 minutes and approximately 50µl
of plasma was collected and immediately stored at -20C. Once all the samples were
collected, samples were thawed, centrifuged at 3,000 rpm for 10 minutes, and 50 µ
supernatant was incubated with Luminex magnetic beads overnight and assayed as
per manufacturer’s instructions (Luminex Multiplex magnetic beads 20-plex Assay,
LMC0006M, Life Technologies) in a black 96-well plate. This assay kit simultane-
ously measures 20 mouse cytokines: GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5,
IL-6, IL-10, IL-12, IL-13, IL-17, TNF-α, IP-10, KC, MCP-1, MIG, MIP-1α, FGF-
basic and VEGF. This assay was measured in collaboration with Anupriya Agarwal,
PhD.
Of the 20 cytokines measured, we chose 10 to report on. These ten (IP-10, IL-
1β, MCP-1, IL-12, MIG, TNF-α, VEGF, IL-2, MIP-1α and IL-6) were significantly
different than baseline levels independent of treatment and had greater than 75%
of the data as measurable, within the standard curve for each cyotokine. For each
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Figure 3.14: Plasma cytokine levels are reported as the difference between the (A)
6 hour or (B) 5 day measurement and the baseline signal for each mouse (n=5, each
treatment). *p≤0.05, multiple t-tests.
mouse, the difference between the signal at the time point measured and the baseline
is reported. We found that IP-10, IL-1β, MCP-1, IL-12, and MIG were significantly
higher in mice treated with Ad compared to SiAd at 6 hours, but at 5 days post-
injection only IL-2 and IL-12 were significantly higher (Figure 3.14). To confirm that
these results were not a result of delivering less viral load, but due to the silica coat we
measured the luciferase signal from both muscles and livers as described previously.
Luciferase expression was comparable and non-significantly different between Ad or
SiAd treatments.
To confirm our findings we performed a second experiment in the same manner
as the first. Five mice were IM injected in both hind limbs with either Ad or SiAd
expressing luciferase at 5x108 PFU, high dose preparation. Plasma was collected
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Figure 3.15: (A) Luciferase expression with Ad (n=10) or SiAd (n=10) treatment.
(B) Representative images. (C) Cytokine levels 6-hours post IM injection normalized
to background. (D) Cytokine levels 6-hours post second injection normalized to
background. *p≤0.05, multiple t-tests.
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Figure 3.16: Raw values from cytokine panel for IP-10, IL-1β, MCP-1, IL-12, and
MIG showing clear spike in levels at 6 hours with Ad treatment (n=10).
at baseline, 6 hours and 5 days post-injection. To test the effect of a second dose,
we took plasma at 16 days post first injection as a new baseline. Then at 21 days
post-injection, we re-administered Ad or SiAd in the same mice and took plasma
6 hours and 5 days post-injection. Again, we saw significant differences for IP-
10 (p≤0.0001), IL-1β (p≤0.0001), MCP-1 (p=0.0001), IL-12 (p=0.0025), and MIG
(p=0.0058) between Ad and SiAd at 6 hours post-injection (Figure 3.15C). Upon
a second injection, the less robust where we only observed significant differences in
IP-10 (p≤0.00001) and IL-1β (p=0.0055) (Figure 3.15D). When looking specifically
at the raw data from both experiments with mice treated with a single injection
for IP-10, IL-1β, MCP-1, IL-12, and MIG, we clearly see changes in cytokine levels
between baseline (0 day), 6 hour and 5 days post injection (Figure 3.16). In mice
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injected with Ad there is a spike in plasma cytokine levels at 6 hours which reduce to
baseline at 5 days. We can also see the variability in baseline cytokine levels in mice.
Luciferase expression was measured for all mice and representative images are shown
(Figure 3.15 A & B). No significant differences were found in luciferase expression
in muscles, however liver transduction was significantly reduced (p=0.04, ONE-way
ANOVA).
We observed that SiAd did not induce any inflammatory cytokines. All of the
elevated cytokines we found in Ad treated mice are involved in the innate immune
response against viral particles. IP-10, also known as CXCL10, is a chemokine that
induces chemotaxis and is associated with infections diseases [6]. It is being studied
as a diagnostic marker for HIV infection and other inflammatory diseases [7]. The IL-
1 family of molecules is another involved in both inflammation and immune response
and is a simulator of T cells [8]. MCP-1, known as monocyte chemoattractant
protein, is as the name implies is a chemokine that induces infiltration of macrophages
[9]. IL-12 is secreted by antigen presenting cells in response to viral and bacterial
infections to induce T cell responses [10]. It is implicated in clearing viral load. Most
studies looking at innate immunity to Ad, have focused on IL-6, TNF-α, and IP-10.
However we did not observe significant differences in IL-6 and TNF-α levels. Koizumi
et al. found that the majority of serum cytokine levels are produced in the spleen
and liver [11]. Though the spleen may accumulate Ad, it does not result in splenic
transduction, which is in contrast to the liver where hepatocyte transduction can
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occur. We did not observe transduction of the spleen, but in Ad treated mice there
was significant liver transduction. Likely we did not deliver sufficient viral load to
observe changes in IL-6 and TNF-α via the IM injection route. Overall, these results
suggest that reduced liver transduction and silica cloaking of Ad can minimize the
systemic innate immune response.
3.2.2 NSG vs. WT Transduction
Comparing the transduction efficiency in immune compromised and immune
competent mice revealed some interesting findings (Figure 3.17). In both types of
mice, mice were IM injected with 5x108 PFU of Ad or SiAd-luc. Note that the
NSG mice were injected with SiAd made from refrozen Ad stock. First, in WT mice
Figure 3.17: Comparison of muscle and liver transduction between NSG and WT
mice IM injected with Ad or SiAd. **p≤0.005, 2way ANOVA.
treated with Ad, both muscles and livers had significantly reduced transduction
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compared to NSG where on average muscle transduction was reduced by 5.4-fold
and liver transduction was reduced by 10 fold (**p≤0.005, 2way ANOVA). Second,
the transduction efficiency of SiAd was non-significantly different between NSG and
WT mice for both muscles and livers. This data supports the hypothesis that in WT
mice, innate immune components (outside of liver sequestration) are clearing naked
Ad particles from the site of injection and circulation in WT mice. However, SiAd
particles behaved similarly in NSG and WT mice and supports the finding that silica
encapsulation does cloak virions from the innate immune system.
3.2.3 Reduced Production of Neutralizing Antibodies
with SiAd Treatment
It is known that antibodies can be produced against foreign pathogens and
materials in immune competent mice, specifically in c57bl/6 mice. This occurs on
the time scale of weeks after exposure to the antigen. From the cytokine experiment,
discussed previously, we had immune competent mice that had received multiple
injections of Ad or SiAd over a 25 day period. plasma was collected from mice 44 days
post primary injection with Ad or SiAd (n=10 total) and frozen at -20C. To detect
the presence of neutralizing antibodies against Ad, a serial dilution neutralization
assay was performed using Ad-luc. Sera were first heat inactivated at 56◦C for
60min and serial 3-fold dilutions were performed starting at 1/100 to 1/218700 at 2x
concentrated in DMEM. Next, 10ul of Ad-luc stock at 1x1010 PFU/ml was diluted to
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5ml and 50ul of viral solution was added to each sera dilution and incubated at 37◦C
for 60min. Then, 100ul of sera dilution + viral solution was added to A549 cells,
which resulted in a MOI 50 as this was in the linear range of luciferase expression.
After 24 hours luciferase expression was measured using ONE-Glo Ex Luciferase
Assay System (Promega) and Tecan Spark 20M. This procedure was adapted from
Sprangers et al. [12].
Figure 3.18: WT mice were injected with Ad or SiAd and plasma was collected.
(A) plasma dilutions were tested for neutralizing antibodies using Ad-luc. (B) The
50% neutralization titer (IC50) was 15-fold higher in mice treated with Ad verus
SiAd. *p≤0.05, t-test.
To compare the amounts of neutralizing antibodies in plasma we plotted as
luciferase expression vs. plasma diltuion (Figure 3.18A). Higher concentrations of
antibody will neutralize Ad-luc and thus result in lower luciferase expression. The
concentration of half max or the concentration at which 50% of virus present is
neutralized (IC50) was determined by linear regression analysis on the linear portion
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of each plasma dilution. The IC50 titer for mice treated with SiAd was 135 ± 40,
but the IC50 of mice treated with Ad was almost 15-fold higher at 2137 ± 652
(Figure 3.18B). The reduction in the concentration of plasma antibodies can be
attributed to both the masking viral antigens by silica and to the overall reduced
liver transduction. Mice injected with SiAd had about 8.5-fold less liver signal as
measured by luciferase. Kuppfer cells in the liver can act as antigen presenting cells
which are crucial to antigen presentation and antibody production. Transduction
of tumor cells does not lead to antigen presentation is one method that tumors
evade immune recognition. Overall, we found that mice treated with SiAd had lower
concentrations of neutralizing antibodies against Ad and suggests that SiAd may
extend the time for repeat injections.
3.3 Summary and Future Directions
The in vivo experiments performed above revealed some very interesting find-
ings in both immune compromised and immune competent mice. IT injections in a
T98G xenograft model showed that SiAd reduced off-target, liver, transduction by
210-fold and enhanced transduction of tumors by 23-fold. We found that tumor CAR
expression changed with passage number, which had a significant impact of Ad trans-
duction efficiency, but not on SiAd. As a model for cancer gene therapy we tested Ad
or SiAd expressing TRAIL and found SiAd significantly inhibited tumor growth. In
immune competent mice we performed IM injections and looked for plasma cytokines
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as a marker for the innate immune response and plasma neutralizing antibodies as
a measure of the adaptive immune response. There was a significant increase in
five plasma cytokines (IP-10, IL-1β, MCP-1, IL-12, and MIG) when comparing Ad
to SiAd at 6 hours post-injection. Not only was there a difference, but SiAd did
not induce any inflammatory cytokines. In addition, we found that mice treated
with SiAd had a significant reduction in plasma neutralizing antibodies against Ad.
Overall this in vivo data shows that silica encapsulation of Ad can address some of
the current barriers to clinical success and even enhance cancer gene therapy while
reducing the overall immune response. In the future, higher doses of virus need to be
tested, doses comparable to ones tested in the clinic. This goes in hand with develop-
ing a method which allows for scale-up of the encapsulation process. One potential
method to assist in the synthesis of higher doses could be the use of microfluidic
reactors, which have been used to synthesize other silica nanoparticles. Independent
of scale-up methods, an actual oncolytic viral with replication capacity needs to be
tested. Unfortunately, in the context of replicative viruses, silica encapsulation can
only minimize innate and adaptive immune responses to the initial dose as progeny
virions are un-encapsulated. More work needs to be done to show that SiAd directly
reduces liver toxicity by looking at transaminase levels, which are elevated in Ad
treatments and by looking for cytokine levels at the tissue scale using qPCR. In the
context of oncolytic viral therapy, a true lytic virus could be enhanced with silica
encapsulation by retaining the particles at the site of interest and minimizing loss to
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the circulation and sequestration by the liver. Adenovirus is ideal model system, but
the field is also focused on other viruses for gene therapy or oncolytic viral therapy.
These other viruses such as herpes simplex or adeno-associated virus also subject to
similar barriers to clinical success and could benefit from a nanoparticle formulation
that enhances transduction while reducing immune responses and liver transduction.
In the context of non-lytic gene therapy, viral vectors can benefit from cloaking
technologies as well to reduce immune responses and increase retention of particles
at the site of injection. Again, delivery of a therapeutic gene needs to be tested.
Mouse models of diseases caused by enzyme deficiencies are available, but the true
test would be to use vectors already in clinical trials such as the AAV vector Glybera
for LPLD. The next chapter describes preliminary work on transferring silica and
other cloaking technology to AAV vectors.
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Chapter 4
Cloaking of Adeno-associated Virus
The use of AAVs for gene addition and gene editing has become a common
approach in the lab and clinic. Currently, there are over 70 clinical trials that are
active or recruiting with an intervention using an AAV vector. Each serotype of
AAV has associated tropism (see 1.2.3) though most studies have focused on AAV2
since it is well characterized and has relatively broad tropsim. Similar to Ad, the
success of AAV vectors in the clinic are influenced by tropism, liver clearance, and
immune responses. Thus we tested applying the knowledge from Chapter 2 for
silica encapsulation of AAV. In addition, we tested a novel method of using exosome
membranes as a cloaking mechanism to form exosome-AAV nanoparticles.
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4.1 Exosome-AAV Nanoparticles
The use of liposomes to encapsulate drugs, proteins, and other biologics is
widespread in biotechnology. Liposomes are spherical vesicles comprised of a one
or more lipid bilayers with an aqueous core. These lipids come is variety of forms,
natural or synthetic, and are composed of hydrophobic tail and a hydrophilic head
group. The amphiphilic (both hydrophobic and hydrophilic) nature of lipids al-
lows them to self assemble into vesicle structures where the hydrophilic head groups
orient toward the inside and outside of the bilayer in aqueous media. In general
liposome preparation consists of three steps: drying down lipids from an organic
solvent phase, reconstituting lipids in an aqueous phase to form vesicles, and then
purifying or extruding vesicles to obtain the desired size. Encapsulation of a desired
entity is controlled through the second step where the aqueous media contains the
protein/drug/enzyme of interest. When PEGylated, liposomes have show signifi-
cantly enhance circulation half-life of drugs in humans and has resulted in a handful
of FDA approved formulations [1]. In the context of transfection, cationic liposomes
have been used to enhance delivery of nucleic acids. Cationic formulations can be
very effective in vitro, but have significant issues in in vivo applications that stem
from the positive surface charge [2]. Recently, extracellular vesicles (EVs), which are
essentially naturally occurring liposomes, have been shown to be efficient carriers
of cellular information (Figure 4.1). We sought to use the membranes of naturally
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derived EVs to form liposome-like nanoparticles that contain or associate with AAVs
to enhance transduction and serve as a cloaking mechanism.
Figure 4.1: Natural exosomes and synthetic liposomes are similar. Reproduced
with permission from [3], copyright Elsevier.
4.1.1 Exosomes
Exosomes are nanoscale vesicles which are a subset of extracellular vesicles
(EVs) that are secreted by all cells. They are turning out to be interesting targets
as therapeutic and diagnostic tools. Initially thought to be cellular debris, EVs have
been found to contain RNA, proteins, and other signaling molecules [4]. Now the
field classifies EVs as intercellular communicators that are capable of transmitting
information from one cell to another and are implicated in tumorgenesis [5]. Recently,
exosome associated AAVs have been found to enhance transduction of specific cells,
both in vitro and in vivo [6]. These exosome associated AAVs were found during
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the exosome purification process, which involves ultracentrifugation. Considering
that AAVs (25 nm) and exosomes (25-100 nm) are similar in size, it is likely that
these two entities are being collected together in the ultracentrifugation process and
thus become ”associated”. Maguire et al. performed TEM on microvesicles and EVs
that were collected from cells producing AAVs and also found AAVs associated with
EVs, but it was not clear from the data published whether AAVs were physically
encapsulated by EVs [7]. We sought to develop a technique to encapsulated AAVs
in exosomes in a controlled manner by adapting methods used for the preparation
of liposomes.
4.1.2 Ex-vivo Exosome-associated AAVs
First, we tested making exosome associated AAVs in a controlled manner ex
vivo. Lyophilized exosomes derived from A549 cells was purchased from Galen Labo-
ratory Supplies (HBM-A549-100/2). The product was diluted in 100µl sterile filtered
water as a stock solution, which resulted in approximately 1x108 particles/µl. Each
sample used 1µl of stock solution. For example, 1µl of stock solution was diluted
in 10µl in water. To mimic exosome associated AAVs, we simply mixed reconsti-
tuted exosomes with AAV2 stock solutions and measured transduction. AAV2 was
purchased from the Molecular Virology Support Core at Oregon Health Sciences Uni-
versity (Beaverton, OR) and was supplied at 4.9x1012 vg/ml stored in DPBS+35mM
NaCl+5% glycerol. First, 11µl (1µl of stock solution diluted in 10µl water) of recon-
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stituted exosomes were re-lyophilized to produce a pale white powder. This powder
was reconstituted again using 10µl of AAV2 stock solution, hand mixed, and diluted
to a final total volume of 50µl in PBS, sample labeled as ExoRecon. In addition,
11µl (1µl of stock solution diluted in 10µl water) of reconstituted exosomes was hand
mixed with AAV2 stock solution and diluted in PBS, sampled labeled as ExoSTD.
All samples were split and half of each sample was bath sonicated (QSonica, New-
ton, CT) on high power for 10 minutes. Samples were tested on A549 cells and
transduction was measured using FACS (BD Aria Fusion) and confocal microscopy
(Zeiss/Yokogawa CSU-X1) 48 hours post-transduction.
Hydrodynamic radius of each sample was measured using dynamic light scat-
tering (DLS) (Figure 4.2). We found that ExoSTD AAV2 had a hydrodynamic radius
of 67.3±2.7 nm and that ReconExo AAV2 had a radius of 76.7±2.7 nm. AAV2 alone
was measured at 85.8±15.9 nm suggesting that without sufficient mixing, AAVs in
5% glycerol are slightly aggregated. Mixing of exosome membranes and AAVs did not
result in large aggregates and these sub-100nm particles are ideal for transduction,
possibly amenable to IV delivery.
We found that by simply mixing AAVs with exosomes or by reconstituting
dried exosome content with an AAV2 solution resulted in enhanced transduction of
cells (Figure 4.3 & 4.4). Sonication is a technique to disrupt lipid membranes and
form unilamellar vesicles. In addition, it can be used to increase drug loading of
liposomes. Here, we used sonication to disrupt reconstituted exosome membranes
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(a) Exosome standard in PBS
(b) Exosome standard mixed with AAV2
(c) Dried lyophilized exosomes reconstituted with AAV2
Figure 4.2: Hydrodynamic Radius of Exosome Associated AAV2
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Figure 4.3: Exosome associated AAVs made ex vivo show enhanced transduction
and protection against bath sonication measured with FACS. ExoSTD AAV2: recon-
stituted exosomes mixed with AAV2. ExoRecon AAV2: dried lyophilized exosomes
mixed with AAV2.
and to potentially increase the association with AAVs. Interestingly, bath sonication
of AAV2 alone significantly reduced transduction whereas sonication had little effect
on exosome associated AAVs. This data suggests that sonication is powerful enough
to disrupt AAV capsids, but for exosome associated AAVs the exosome membrane
is shielding capsids from this effect. Further TEM analysis can reveal how AAVs are
associated with exosomes using this simple method.
4.1.3 Exosome Membrane Liposomes with AAV2
Standard techniques to produce liposomes use lipids which are solubilized in
organic solvents. The lipids are extracted by removing the solvent using a vacuum
or simple evaporation and then further desiccated to remove all residual solvent.
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Figure 4.4: Exosome associated AAVs made ex vivo show enhanced transduction
measured by confocal microscopy. ExoSTD AAV2: reconstituted exosomes mixed
with AAV2. ExoRecon AAV2: dried lyophilized exosomes mixed with AAV2.
Drying of lipids results in the formation of a thin film, which can then be hydrated
in aqueous media to form lipid vesicles [8]. We applied this simple technique to
extract lipids and associated content from exosomes. Lyophilized exosomes derived
from A549 cells was purchased from Galen Laboratory Supplies (HBM-A549-100/2).
The product was diluted in 100µl sterile filtered water as a stock solution stored at
4C. To solubilize the lipids and exosomal contents, an aliquot of stock solution was
lyophilized to a dry white powder in a glass vial. This powder was then dissolved in
50µl of either ethanol (EtOH) or chloroform (CHCl3). Both solvents are regularly
used as a solvent for lipids and we found that exosomes were also soluble in both
solvents with vortexing and bath sonication. The solvent was then removed under
vacuum and further desiccated to produce a thin film. This film was then rehydrated
with an AAV2 solution diluted in PBS and mixed by hand. Samples were tested on
T98G cells and transduction was measured using confocal microscopy. Note that
exosomes were derived from A549.
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Figure 4.5: Transduction of rehydrated exosomes with AAV2 tested on T98G cells.
We found that rehydrating exosomal contents with an AAV2 solution en-
hanced transduction on T98G cells. AAV2 alone had low levels of transduction,
grayscale mean = 2.1, which was slightly aided by mixing with exosomes in solution,
grayscale mean = 7.3, see sample labeled “ExoSTD AAV2” (Figure 4.5). This is
similair to exosome associated AAVs. Both samples generated from thin film hy-
dration,“ExoEtOH AAV2” from ethanol and “ExoChCl3 AAV2” from choloroform,
using an AAV2 solution showed enhanced transduction with grayscale mean values
of 10.7 and 10.8, respectively (Figure 4.5). This suggests that thin film hydration
allows the exosome membrane to encapsulate AAV virions and enhance cellular up-
take. The literature suggests that exosomes can be very specific delivery vehicles,
though here we saw that A549 exosomes are capable of delivering to T98G cells.
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This is supported by other studies that showed there are degrees of specificity, where
exosomes from one cell line are capable of transfecting other cell lines [9].
Overall, this preliminary data suggests that exosomes can enhance AAV trans-
duction in vitro whether simply through association or as a liposomal formulation.
Further studies need to be performed to show that AAVs are physically encapsulated
in exosomes made as a liposomal formulation. An indirect measure of encapsulation
would be to use an AAV that has narrower tropism and show that exosome encap-
sulation expands this tropsim to cells not normally transduced by AAV alone. In
addition, the effect of solvents on exosome membrane proteins and exosome contents
was unexplored. Potentially harsh solvents can denature proteins, rendering them
non-functional though the results above suggest otherwise.
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4.2 Silica-AAV Nanoparticles
Taking what we learned from silica encapsulation of adenovirus (Ad), we
briefly tested silica encapsulation of AAVs using the same method as described in
Chapter 2 of this dissertation. AAVs are composed of a pure capsid protein structure
that is similar to Ad and thus can be used for template driven silica deposition. The
zeta potential of AAV2 was measured as approximately -20 mV making it amenable
to cationic PLL masking through electrostatic interactions. Similar to SiAd synthe-
sis, 5µl of AAV2 stock solution at 4.9x1011 vg/ml (Oregon National Primate Research
Center, Beaverton, OR) was incubated with 1.5µl PLL solution (300k+ MW 0.1%
w/v) for 15 minutes and bath sonicated for 3 minutes on low power. TMOS was hy-
drolyzed to form silicic acid and 1.5 µl of 3.6% v/v silicic acid was added. The total
reaction volume was diluted to 30µl in 0.05x PBS and vortexed at RT for 2.5 hours.
Samples were tested on HeLa cells at various MOIs and fluorescence was measured
using confocal microscopy (Zeiss/Yokogawa CSU-X1) at 48 hours post-transduction.
Characterization of particles using DLS and transmission electron microscopy
(TEM) revealed conflicting results. By DLS (Zetasizer Nano) we measured the hy-
drodynamic radius of AAV2 at 43.5 ± 3nm and of SiAAV2 at 39.3 ± 1.8nm (Figure
4.6). Neat AAV2 theoretically has a diameter of about 25nm suggesting that AAV2
is slightly aggregated in solution. Surprisingly, SiAAV2 was measured as having a
similar size by DLS, which at first suggested that silica encapsulation did not occur.
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(a) Hydrodynamic Radius of AAV2
(b) Hyrdrodynamic Radius of SiAAV2
Figure 4.6: Hydrodynamic Radius of Silica Encapsulated AAV2
Using TEM we found large aggregates of particles for both AAV2 and SiAAV2 (Fig-
ure 4.7). These aggregates are possibly due to the drying of particles on the grid.
Similar aggregate structures, on the order of hundreds on nanometers, with sinew-
like connections were found in both samples. These large structures are in contrast
to the DLS data above. Similar to previous TEM studies, imaging of AAV2 required
the use of negative stain (uranyl acetate), however SiAAV2 was imaged without the
use of negative stain, confirming that silica was present. Unlike proteins and lipids
silica provides sufficient electron density for electron microscopy.
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Figure 4.7: TEM of AAV2 stained with uranyl acetate and of SiAAV2 without the
use of negative stain. Scale bars represent 100nm.
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Figure 4.8: Enhanced transduction with SiAAV2 on HeLa cells as measured by
confocal microscopy.
Particles were tested on HeLa cells and GFP fluoresence was measured at 48
hours. AAV2 is reported as having tropsim for HeLa [10]. We found that SiAAV2
significantly enhanced transduction at both MOIs tested (Figure 4.8). At the high
MOI, mean grayscale values for AAV2 and SiAAV2 were 1.96 and 18.1, respectively.
At the low MOI, mean grayscale values for AAV2 and SiAAV2 were 0.40 and 6.97, re-
spectively. These preliminary experiments suggest that silica encapsulation of AAVs
follows similar characteristics as encapsulation of Ads. Further optimization of silica
reaction conditions needs to be explored.
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4.3 Summary and Future Directions
The use of AAVs for gene therapy and for gene editing has exploded in the
last ten years because AAVs have many ideal characteristics for in vivo applica-
tions. However, the barriers to clinical efficacy are similar to Ad: tropsim limits
or defines AAV efficiency to cell types, liver clearance efficiently clears virions from
the circulation, and immune responses both innate and adaptive limit the use of
repeated injections, which are necessary. Encapsulation whether with an exosomal
membrane or with silica was explored to address some of these challenges. Prelim-
inary studies showed that both methods can enhance AAV transduction in vitro.
The use of exosome membranes could allow for IV delivery without the use of PEG
since exosomes are of human origin and can be patient derived. Future work will
focus on testing CRISPR-CAS9 delivery using AAVs and showing efficacy in animal
models. For gene editing in vivo, generally two viruses are used: one to deliver the
Cas9 gene and another to deliver the guide RNA product and/or the donor DNA
template. Either exosomal or silica encapsulation could enhance the delivery of both
virions to the same cell and thus improve the efficiency of gene editing while reducing
immunogenicity.
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Appendix A
Final notes
We have shown that taking methods and materials from the nanoparticle field
can augment the delivery viral vectors for therapeutic applications. In a sense these
methods are allowing us to surpass viral evolution by enhancing transduction of cells
independent of receptor-ligand transduction. There is still significant work to be done
on further designing silica based coatings to not only enhance transduction, but also
to add back desired specificity through silanol chemistry. We used adenovirus (Ad)
as an ideal model system, but cloaking technologies can be applied to other clini-
cally relevant viral vectors such as adeno-associated virus (AAV) or the integrating,
enveloped vector lentivirus. Cloaking technologies are promising for minimizing im-
mune responses associated with viral vectors. Here, we showed that silica cloaking
of Ad elicited no inflammatory cytokines and reduced the production of neutralizing
antibodies. This result is also important for and applicable to AAV vectors, which
are commonly being tested for gene therapy therapies. For example, we can combine
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multiple vectors into a single entity to improve efficiency with cloaking attributes.
This is especially pertinent for therapies based off genome editing, which require mul-
tiple components to be delivered in a single cell. In vivo genome editing use AAVs
is currently inefficient due to this factor. In addition, the production of neutralizing
antibodies prevents re-administration of the vectors. The combination of synthetic
and biologic components allows us to address issues associated with both and to
exploit synergy for meaningful outcomes. This dissertation serves as a jumping off
point for continuing work in this field and hopefully leads to advancements in the
clinic.
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